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1. Introduction
Antibodies are binding molecules (affinity reagents) that have a high specificity for their 
unique target (antigen) and are crucial tools for research, diagnostics, therapeutics and 
regulatory procedures. Animals are still used for the generation of monoclonal and 
polyclonal antibodies as well as other types of affinity reagents despite the availability of 
technologies for their development and production that do not entail the use of animals. 
The EU Directive 2010/63/EU on the protection of animals used for scientific purposes 
does not allow the use of animal-based methods when other methods not entailing the 
use of animals exist, which would allow obtaining the results sought (Articles 4 “Principle 
of replacement, reduction and refinement” and 13 “Choice of method”).
The EU Reference Laboratory for alternatives to animal testing (EURL ECVAM) avails of 
the scientific opinion of the EURL ECVAM Scientific Advisory Committee (ESAC) about 
specific issues related to alternative methods. In 1998, based on the available evidence, 
ESAC concluded that for all levels of monoclonal antibody production, scientifically 
acceptable in vitro methods (i.e. use of hybridomas) were practicably available and 
that these methods were either better than, or equal to, the in vivo (ascites) production 
method in terms of antibody quality. Thus, the ESAC stated in 1998 that in vivo production 
of monoclonal antibodies by the ascites method was no longer scientifically necessary, 
except in rare cases1. Nevertheless, the recent statistical information published by the 
European Commission on the use of animals for scientific purposes in the EU show an 
increase by 65% in the use of animals for monoclonal antibody production by the mouse 
ascites method between 2015 (27333 animals used) and 2017 (45024 animals used). 
It is unclear from the non-technical project summaries how the ascites method could be 
justified and as a consequence, why such projects could still be authorised in EU countries.
Although animal-use statistics do not indicate the total number of animals used for 
generation and production of antibodies beyond the ascites method, it is well known 
that animal immunisation is still widely used for the development of hybridomas for 
monoclonal antibody production and that the largest proportion of animals used is 
for producing polyclonal antibodies. It is estimated that close to 1 million animals 
are used per year for antibody development and production in the EU alone. Several 
factors contribute to the slow transition from animal-derived to non-animal-derived 
affinity reagents used by the scientific community. Commercial availability of non-
animal-derived affinity reagents is limited since the majority of providers still generate 
antibodies by animal immunisation. Moreover, many misconceptions exist in the scientific 
community about the quality and validity of non-animal-derived affinity reagents; 
a problem that is compounded by a lack of education and training opportunities for 
users to gain a better understanding and appreciation of non-animal-derived affinity 
reagents and how they can ultimately benefit their work.
2. ESAC review and EURL ECVAM position
In March 2018, EURL ECVAM asked ESAC to review the scientific validity of non-animal-
derived antibodies and non-antibody affinity reagents used for research and applications 
in regulatory and diagnostic fields. Based on its independent scientific peer review, the 
ESAC produced an Opinion on the  on the "Scientific validity of replacements for animal-
derived antibodies" (Annex 1), supported by an ESAC Working Group report (Annex 2).
In its review, the ESAC focused on non-animal-derived antibodies generated by phage-
display, where a bacteriophage is genetically modified to display an antibody, since 
this is the most mature technology. As noted by the ESAC, the 2018 Nobel Prize in 
Chemistry was awarded “for the phage display of peptides and antibodies”. The phage-
display technology for antibody production involves the use of large collections of 
1 https://tsar.jrc.ec.europa.eu/test-method/tm1998-04
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recombinant forms of antibody analogues or of miniaturised antibodies that contain 
at least part of the antigen-binding site of an antibody such as single variable heavy 
(VH) domain, single-chain fragment variable (scFv) and fragment antigen binding (Fab). 
In this approach, large binder libraries are presented on the surface of a phage (i.e. 
phage display), which permits the selection of peptides or proteins with high affinity 
and specificity for virtually any target. Such recombinant antibodies produced by phage 
display are already widely used across all fields of antibody application.
The ESAC also briefly discussed new alternative binders that are being introduced in the 
market, such as aptamers, affimers, DARPINs. These alternative binders can be based 
on peptides, proteins, ribonucleic acids, or single-stranded DNA. Although these new 
molecules are already being applied in diagnostics, antibodies are still the molecules 
of choice for many applications. The ESAC recommended that a more detailed review 
of such alternative affinity reagents is conducted in the future once more data become 
available (see Annex 2 - ESAC Working Group report).
Based on the available scientific literature, application examples and the experts’ own 
extensive experience, the ESAC concluded that non-animal-derived antibodies are mature 
reagents generated by a proven technology that are not only equivalent to animal-
derived antibodies, but in many respects can offer significant scientific advantages and 
economic benefits (see Annex 1 - ESAC Opinion and Annex 2 – ESAC Working Group 
report). Non-animal-derived antibodies are well-defined and better reagents that will 
improve the reproducibility and relevance of scientific procedures and lead to more 
efficient and effective use of research funds. Animal-derived antibodies typically suffer 
from batch-to-batch variability and many show low specificity. Such issues can be easily 
addressed through the use of non-animal-derived antibodies obtained by phage-display 
technology. Equally, antibodies used for regulatory applications, e.g., reagents used in 
toxicity tests or for the quality control of biologicals, should be non-animal-derived. This 
will enhance reproducibility of results and the sustainable supply of reagents.
Animal-derived polyclonal antibodies make up a large proportion of animals used today 
for antibody production and, therefore, present serious ethical concerns. However, they 
can be produced using defined mixtures of sequence-defined recombinant antibodies 
developed from universal phage display libraries, thereby avoiding the use of animals. 
These so-called “multiclonal” antibodies2 have been recently shown to exceed the 
performance of the monoclonal products3. These recent developments also show that 
non-animal-derived “multiclonal” antibodies with superior quality (e.g., lower unspecific 
reactions) and higher reproducibility over animal-derived polyclonal antibodies can and 
should be generated. It is therefore possible to combine the best features of monoclonal 
and polyclonal antibodies in a completely animal-free and defined product.
Even though the ESAC review did not cover the field of therapeutic applications, EURL 
ECVAM considers that non-animal-derived antibodies are also a suitable alternative in 
this field. In fact, monoclonal affinity reagents approved for therapeutic applications are 
nowadays exclusively recombinant, well characterised because of strict regulations, and 
stably produced in large amounts. However, while several of these affinity reagents are 
non-animal-derived, most of them are still generated by immunising animals without 
a clear need or justification.
Therefore, taking into consideration the ESAC Opinion on the scientific validity 
of replacements for animal-derived antibodies, EURL ECVAM recommends 
that animals should no longer be used for the development and production of 
antibodies for research, regulatory, diagnostic and therapeutic applications. The 
provisions of Directive 2010/63/EU should be respected and EU countries should 
no longer authorise the development and production of antibodies through animal 
immunisation, where robust, legitimate scientific justification is lacking.
2 https://abcalis.com/multiclonals
3 https://www.abcalis.com/releases/ABCALIS_TechNote_Multiclonals.pdf
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"EURL ECVAM recommends 
that animals should no 
longer be used for the 
development and production 
of antibodies for research, 
regulatory, diagnostic and 
therapeutic applications. 
In the EU, the provisions of 
Directive 2010/63/EU should 
be respected and EU countries 
should no longer authorise the 
development and production 
of antibodies through 
animal immunisation, where 
robust, legitimate scientific 
justification is lacking."
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3. Breaking down misconceptions about non-animal-
derived affinity reagents
Availability, quality and relevance of non-animal-derived antibodies
 ͹ Non-animal-derived antibodies are available from catalogues. Companies and 
other organisations offer custom generation of non-animal-derived antibodies 
(see Section V in the Appendix of Annex 2 - ESAC Working Group report).
 ͹ There is a wealth of scientific literature describing various approaches for 
generating non-animal-derived antibodies, for example, building of universal 
recombinant antibody gene libraries, antigen selection and production (see 
Section 10 of Annex 2 - ESAC Working Group report).
 ͹ Non-animal-derived antibodies can be stably produced in unlimited amounts 
as the example of approved therapeutics shows.
 ͹ Non-animal-derived antibodies are equivalent to animal-derived antibodies 
for the vast majority of applications. There are no general or systematic 
disadvantages of non-animal-derived antibodies with respect to properties 
such as affinity, stability/shelf life, and specificity. On the contrary, they can 
offer significant scientific advantages (see "Scientific benefits" below).
 ͹ To date most of the recombinant antibody gene libraries have been built 
using human antibody sequences as a blueprint; however, there are no 
known limits concerning the choice of the species for building such libraries 
and there are some examples available.
Equipment, expertise, resources
 ͹ Only standard laboratory equipment and consumables are needed for 
generating non-animal-derived antibodies.
 ͹ Laboratories familiar with modern molecular, cell and microbiology 
techniques should be able to generate non-animal-derived antibodies once 
adequately trained.
 ͹ Development of a universal recombinant library requires a significant time 
investment, ranging from a few months to a couple of years, which is very 
much dependent on the approach used, level of expertise and quality control; 
however, once the library is developed, this supplies a diversity of antibody 
candidates equivalent to a lifetime supply of animals and removes any 
ongoing cost of animal care, where relevant.
 ͹ However, there is a significant benefit in time: selection of antibodies using 
a universal recombinant library can be performed in a few weeks, while the 
generation of animal-derived monoclonal antibodies needs several months.
Economic benefits
 ͹ Generation costs of non-animal-derived antibodies are comparable to the 
generation of monoclonal antibodies by immunisation.
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 ͹ The financial impact of producing animal-derived polyclonal or monoclonal 
antibodies of questionable quality and using them in research and regulatory 
applications to obtain results that are potentially meaningless is high and far 
exceeds the costs of generating well-defined non-animal-derived affinity reagents.
 ͹ It is estimated that many hundreds of millions of euro are inadvertently 
spent annually by the biomedical research community on non-specific and 
badly defined animal-derived antibodies. Moreover, significant losses are 
also being incurred as a consequence through associated waste of time and 
resources and the follow-up of potentially misleading research results (see 
Section 6 of Annex 2 – ESAC Working Group report).
Scientific benefits
 ͹ Many of the animal-derived antibodies, in particular, polyclonal antibodies, 
have limitations with both specificity and reproducibility. The generation 
methods for animal-derived antibodies have not significantly improved in 
response to these known issues over the past 40 years, nor have they been 
rigorously quality-controlled in light of the above problems.
 ͹ In contrast, non-animal-derived monoclonal antibodies can be generated 
with superior properties and their properties can further be improved by in 
vitro evolution after initial generation.
 ͹ “Multiclonal” antibodies exceeding the performance of monoclonal products 
and with superior quality (e.g., lower unspecific reactions) over animal-
derived polyclonal antibodies from catalogues can also be produced using 
defined mixtures of sequence-defined recombinant antibodies developed 
from universal phage display libraries4,5.
 ͹ In vitro antibody selection against a target antigen can be tightly controlled 
to enrich clones with desired properties. For example, one can do the affinity 
selection with the exact biochemical conditions under which the antibody will be 
used, and therefore, select only antibodies that are functional at these conditions.
 ͹ The sequences of non-animal-derived antibodies are typically determined as 
part of their isolation process. This ensures unlimited supply with antibodies 
of the same quality and increases the reproducibility of scientific experiments.
 ͹ The genetic sequence of a non-animal-derived antibody can be modified 
to add a multitude of features including a variety of antibody formats and 
detection systems (e.g., fusion to tags, enzymes, etc.). The possibility of adding 
a detection system of choice, in particular, has the advantage of decreasing 
the need for labelled secondary antibodies. One can also envision the 
development of a non-animal-derived universal labelled secondary antibody.
 ͹ While most animal-derived antibodies are in the immunoglobulin G (IgG) 
format, recombinant technologies offer additional opportunities to generate 
a variety of formats, e.g., full-length IgG functionally indistinguishable from 
animal-derived IgGs in all typical applications, or antibody fragments.
 ͹ Non-animal-derived antibodies can be used in typical immune-analysis 
applications, for example, western blotting, immunohistochemistry, flow 
cytometry, immunosorbent assays, immunoprecipitation, and multiplexed 
planar or bead arrays.
4 https://abcalis.com/multiclonals
5 https://www.abcalis.com/releases/ABCALIS_TechNote_Multiclonals.pdf
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4. How can the EU promote the generation and use of 
non-animal-derived antibodies?
Education and training
 ͹ Competency of all users and developers/producers of antibodies in non-animal 
technologies such as phage display could be increased/improved by offering 
training, e.g., webinars, e-learning, hands-on training courses. Such training should 
also be included in courses on laboratory animal science.
 ͹ The abundance of scientific literature describing approaches for the development, 
selection and production of non-animal-derived antibodies as well as the 
experiences of users, developers/producers should be leveraged.
 ͹ Education and training should extend beyond end-users, to include suppliers, 
funders, ethical review bodies, publishers, and other bodies.
 ͹ Education should also be used to convey the scientific and economic limitations 
of the animal-based methods of antibody production, challenging the widely held 
belief that animal models are the “gold standard”.
Authorisation of projects in the light of 2010/63/EU
 ͹ Since phage display is a mature and proven non-animal technology for the 
development and production of reliable and relevant antibodies or affinity reagents, 
projects requesting authorisation for the use of animals for these purposes should 
systematically be challenged (in line with Articles 4 and 13 of Directive 2010/63/EU) 
and rejected by the authorising bodies where robust, legitimate scientific justification 
is lacking. In the light of the ESAC Opinion (Annex 1) and the ESAC Working Group 
report (Annex 2), no scientifically justified exceptions could be identified.
 ͹ Antibody production using the ascites method should no longer be acceptable 
under any circumstances.
Publicly and privately funded research projects in the EU (i.e., EU funding, 
national funding and private funding)
 ͹ In the interest of ethical standards and quality of science, any newly generated 
antibody (or more generally any binding reagent) should be detailed in a funding 
application, and, where possible, be non-animal-derived. Robust, legitimate 
scientific justification should be provided for the use of animals to generate and 
produce antibodies.
 ͹ Any binding reagent used or purchased for the project should ideally be non-animal-
derived (i.e., not requiring animal immunisation) and this should also be specified 
in a funding application. Existing, sequenced and well-characterised hybridomas 
may continue to be used to produce recombinant monoclonal antibodies in vitro as 
animals are no longer involved.
 ͹ A transition towards the use of non-animal-derived antibodies in the scientific 
community will be promoted if funding opportunities increase with the use of 
non-animal-derived affinity reagents, creating incentive for the use of non-animal-
derived products.
10  |  EURL ECVAM RECOMMENDATION 
Provision of funding to fully characterise affinity reagents generated in EU 
(and US NIH)-funded programmes
 ͹ EU (and US NIH)-funded programmes have already generated thousands of affinity 
reagents without using animals, which should be disseminated to researchers 
(see Section III in the Appendix of Annex 2 – ESAC Working Group report). Further 
funding and efforts are needed to prioritise and fully characterise these reagents 
and make them available to scientists.
5. What should antibody manufacturers/suppliers do?
 ͹ Manufacturers/suppliers should replace the animal-derived antibodies available 
in their catalogues (especially those produced by the ascites method) by 
non-animal-derived affinity reagents and clearly describe their origin and 
development in the accompanying product literature. Existing, sequenced and 
well-characterised hybridomas may continue to be used to produce recombinant 
monoclonal antibodies in vitro as animals are no longer involved in the production 
of the antibodies.
 ͹ Manufacturers/suppliers should establish a rapid phasing-out timescale (with 
regularly reviewed targets and deadlines) and provide regular updates to the 
authorities (under Directive 2010/63/EU) until animals are no longer used for 
antibody generation and production.
 ͹ Manufacturers/suppliers should form partnerships, e.g., with other companies, 
academics, non-governmental organisations and/or government agencies, to 
increase the production and availability of non-animal-derived antibodies.
 ͹ All catalogue affinity reagents should be unambiguously labelled to show whether 
they are animal-derived or not.
6. What should end-users do?
 ͹ End-users should search for and specifically request well-defined, non-animal-
derived affinity reagents from suppliers to address their research/regulatory 
questions and coordinate to develop a platform to assist in future searches. Higher 
demand will increase the production and eventually decrease the costs.
 ͹ Academic institutions should coordinate efforts to establish non-animal-derived 
universal recombinant libraries and development and production services to 
support research activities.
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7. What should editors, reviewers and publishers do?
 ͹ Editors, reviewers and publishers of scientific publications should demand higher 
quality in antibody-based research, strive for increased scientific standards and 
adopt unified validation standards for affinity reagents used in their publications. 
Authors of scientific reports or articles should be requested to state the source of 
the affinity reagents used, whether they are animal-derived or non-animal-derived, 
and how their quality and relevance (affinity and specificity) were controlled/
ensured. If animal-derived antibodies have been used, clear justification should 
be provided.
 ͹ Manuscripts with results obtained using poor quality and/or undefined antibodies 
should be systematically rejected.
 ͹ Applying stricter journal policies of challenging and eventually not accepting 
manuscripts with data generated with animal-derived antibodies where a non-
animal alternative could have been used would further accelerate a transition 
towards the use of non-animal-derived antibodies by the scientific community. 
Editors and publishers should nevertheless adopt a reasonable timeframe for 
applying such stricter policies considering the widespread use of animal-derived 
antibodies in research and the fact that antibody storage ‘shelf life’ may range 
from several weeks to many years.
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Annex 1
ESAC OPINION
ON THE SCIENTIFIC VALIDITY OF REPLACEMENTS 
FOR ANIMAL-DERIVED ANTIBODIES
EURL ECVAM Scientific Advisory Committee (ESAC)
Core Members
• Dr. Chantra ESKES (ESAC Chair)
• Prof. Paula M. ALVES
• Dr. Rebecca CLEWELL
• Prof. Emanuela CORSINI
• Prof. Ian COTGREAVE
• Prof. Annette KOPP-SCHNEIDER
• Dr. José Maria NAVAS ANTÓN
• Prof. Aldert PIERSMA
• Dr. Carl WESTMORELAND
Ad-hoc Members
• Prof. Carl BORREBAECK
• Dr. Andrew BRADBURY
• Prof. Stefan DÜBEL
• Dr. Alison GRAY
• Dr. Hans-Joachim KNAPPIK
• Prof. Andreas PLÜCKTHUN
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The EURL ECVAM Scientific Advisory Committee (ESAC) was requested by EURL ECVAM 
to review the available proof of the scientific validity of antibodies and non-antibody 
affinity reagents, used in research, regulatory applications and diagnostics, generated 
using animal-free technologies. An ESAC working group (WG) was established for this 
purpose, which delivered an ESAC WG report (Annex 2).
At its 45th meeting, held on 3-5 June 2019 at EURL ECVAM, Ispra, Italy, the non-
Commission members of ESAC unanimously endorsed the following opinion, which was 
based on the existing scientific literature, application examples and the experts’ own 
extensive experience as detailed in the ESAC WG report (Annex 2).
1 Non-animal-derived antibodies are mature reagents generated by a proven technology.
Non-animal-derived antibodies, in particular those generated by display of combinatorial 
antibody gene libraries, have matured to a point where, for the vast majority of 
applications, namely all known applications where non-animal-derived antibodies have 
been developed, they are equivalent to animal-derived antibodies. There is a solid body 
of evidence demonstrating that there are no general or systematic disadvantages of 
non-animal-derived antibodies with respect to properties such as affinity, stability/shelf 
life, and specificity.
Non-animal-derived antibodies can be provided in all well-known molecular formats 
(e.g., Immunoglobulin G) and therefore with properties indistinguishable from animal-
derived antibodies. Moreover, they can be produced in additional molecular formats 
that can offer significant advantages (see below).
Many scientists are unaware of the fact that non-animal-derived antibodies are already 
successfully used in approved therapeutics, diagnostic applications and available from 
catalogues as research reagents. Generation of non-animal-derived antibodies is also 
available as a commercial service. EU- and US NIH-funded programmes have already 
generated thousands of monoclonal affinity reagents without the use of animals.
2 Non-animal-derived antibodies offer significant additional scientific benefits.
Non-animal-derived antibodies are superior defined reagents because their polypeptide 
sequences are established as part of the generation process. This is not the case for 
animal-derived antibodies (including monoclonal antibodies), the sequences of which 
are unknown, unless specific efforts are made to determine them.
The knowledge of the sequence provides a unique identifier as well as an unlimited 
and sustainable supply, which will improve experimental reproducibility. For example, 
in contrast to a not uncommon loss of hybridoma clones that normally cannot be 
regenerated, an identical non-animal-derived antibody or scaffold can always be 
generated from its known sequence. Furthermore, it makes these reagents amenable 
to adaptation to end users’ assays, for example by freely choosing the Fc-part to fit the 
individual user’s detection system.
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Methods such as phage display, for which the 2018 Nobel Prize in Chemistry was 
awarded, offer further opportunities, like the use of other binder scaffolds, and allow 
the guided selection of essential characteristics, including specificity, compatibility 
to certain assay conditions, cross-reactivities, stability or affinity, which cannot be 
accomplished by animal immunisation. In summary, biochemical properties can be 
improved by in vitro evolution.
3 Non-animal-derived antibodies should be promoted.
It is the experts’ opinion that adoption of these technologies in research has been 
too slow because there are still only a few providers that offer such reagents for the 
research market; the majority of developers are focused on therapeutic applications. 
Although intellectual property rights have been an issue in the past, most key 
patents have now expired. Today, the upfront cost of generating non-animal-derived 
recombinant reagents is about the same as traditional monoclonal antibodies, but 
significantly more than traditional polyclonal antibodies. However, there are multiple 
issues associated with polyclonal antibodies, which have a direct negative impact on 
the cost of research. The financial impact of producing and using questionable-quality 
polyclonal or monoclonal antibodies in research and regulatory applications is high and 
far exceeds the costs of the reagents themselves, considering the costs of generating 
results that are potentially meaningless.
The experts identified a lack of awareness about the current status of non-animal-
derived antibodies, resulting in significant scientific misconceptions regarding these 
reagents. Education on the properties, availability and specific additional advantages 
of non-animal-derived affinity reagents is needed. Training on the implementation of 
these technologies must also be improved.
4 CONCLUSION
The experts conclude on the scientific evidence that non-animal-derived antibodies are 
able to replace animal derived antibodies in the vast majority of applications. Moreover, 
well-characterised, recombinant affinity reagents will improve the reproducibility of 
science and positively impact society.
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Annex 2
ESAC WORKING GROUP REPORT
ON THE SCIENTIFIC VALIDITY OF REPLACEMENTS 
FOR ANIMAL-DERIVED ANTIBODIES
EURL ECVAM Scientific Advisory Committee (ESAC)
ESAC Working Group
• Dr. Rebecca CLEWELL (WG Chair)
• Dr. Carl WESTMORELAND
• Prof. Carl BORREBAECK
• Dr. Andrew BRADBURY
• Prof. Stefan DÜBEL
• Dr. Alison GRAY
• Dr. Hans-Joachim KNAPPIK
• Prof. Andreas PLÜCKTHUN
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Executive summary
Antibodies bind to and thereby identify specific 
targets of interest in very complex environments 
of other biomolecules. At present, almost all 
(polyclonal or monoclonal) antibodies are produced 
by immunising animals. They are used in immuno-
analysis applications such as Western blotting, 
immunohistochemistry (IHC), immunocytochemistry 
(ICC), flow cytometry, immunosorbent assays (ELISA) 
and immunoprecipitation, and being relied upon by 
all market sectors such as in the development of 
therapeutics, in diagnostics, in research discovery 
and in regulatory applications.
Representing the largest fraction of commercial 
antibody reagents, polyclonal antibodies are 
characterised by multiple epitope recognition. They 
often have high overall antibody affinity against the 
target antigen, offer good sensitivity, are inexpensive 
and quick to produce. However, they suffer issues 
of batch-to-batch variation, low specificity and high 
detection background.
Monoclonal antibodies from hybridomas are in 
principle characterised by single epitope recognition 
and are thought to bind with high specificity to only 
one unique epitope, with reduced probability of cross-
reactivity. Nonetheless, many monoclonal antibodies 
used in research were found to still cross-react with 
other molecules. Moreover, a recent study has shown 
that almost a third of randomly chosen hybridomas 
contained one or more additional productive heavy 
or light chains that interfered with specificity or 
sensitivity (Bradbury et al., 2018). In addition, 
hybridoma clones can die off and be lost.
The resounding impact on research, of using non-
specific antibody reagents, in terms of wasted cost, 
time and resources, or the repercussion on diagnosis 
and health management, is tremendous. Whilst the 
reagents used in most clinical trials and especially in 
medical procedures cleared by the US Food and Drug 
Administration or the European Medicines Agency 
are extremely reliable, such abnormalities go largely 
unnoticed in cases where antibodies are not validated 
to the same degree. At an annual worldwide spending 
of $1.6 billion on the antibody market, and with only 
5-49% functionality being reported in monoclonal 
reagents alone, a staggering annual loss of at least 
$800 million to the biomedical research community 
is estimated, without counting the additional and 
unaccounted cost for waste in materials, time, money 
and follow-on research.
Recombinant antibodies can be animal-derived: 
generated by cloning the antibody-encoding DNA 
of hybridomas or by cloning of antibody gene 
repertoires from B-cells of immunised animals. 
Recombinant antibodies can also be non-animal-
derived, i.e., obtained without using animals: from 
“universal” gene repertoires of non-immunised 
(naïve) donor B-cells, from completely synthetic 
universal antibody libraries, or from cloning the 
antibody DNA from human donor B-cells, e.g., from 
a patient after an infection.
Libraries obtained from an immunised animal are 
already enriched for antibodies that bind a specific 
antigen but require the time-consuming generation 
of a new library for each new antigen of interest. In 
contrast, universal libraries are independent of any 
living organism and can be used time and again to 
enrich specific antibodies.
Such non-animal-derived antibodies have been 
proven as suitable replacements for applications 
that currently employ animal-derived antibodies. 
It is worthy of note that the use of non-animal-
derived antibodies in therapeutic applications is 
well established. Non-animal-derived antibodies 
are selected in vitro from large gene libraries 
predominantly by phage and yeast display, and less 
commonly by ribosome, bacterial or mammalian 
cell display. Such libraries are typically built using 
immunoglobulin domains as scaffolds, but there is 
an increasing list of publications where libraries are 
built on non-antibody scaffolds. This report focusses 
on non-animal-derived antibodies produced by 
phage display, since they are leading in respect of 
technological maturation and compatibility to the 
usual scientific applications, with large bodies of 
evidence supporting their use and fewest perceived 
hurdles to rapid implementation, but the field is 
rapidly developing and diversifying.
Non-animal-derived, naïve or synthetic, universal 
libraries can contain an enormous repertoire of 
structurally different candidate antibody genes 
(typically more than 1010 independent clones). 
This diversity is equal to or even larger than 
that of a naïve immune system prior to affinity 
maturation, and thus provides similar or even better 
opportunities to identify a specific binder against 
any target antigen. Non-animal-derived antibodies 
are routinely sequenced after isolation and 
therefore unambiguously identifiable, which allows 
a consistent, reproducible and sustainable supply. 
Furthermore, their sequence can be immortalised 
in a computer file. These factors offer the benefit 
of improved quality of scientific data over that of 
animal-derived antibodies. The in vitro antibody 
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selection against a target antigen can be tightly 
controlled to enrich clones with desired properties 
such as epitope specificity, stability, expression yield 
or affinity. The genetic sequence can be modified 
to add a multitude of features including a variety 
of antibody formats and detection systems. In 
addition, the availability of the sequence allows 
for applications such as functioning as intrabodies, 
expression on cells as chimeric antigen receptors 
and redirection of viruses to infect particular cell 
types. Non-animal-derived recombinant antibodies 
may also be used for multiple epitope recognition 
where animal-derived polyclonal antibodies are 
traditionally used.
Once a large non-animal-derived antibody library 
is established, it can replace a lifetime supply of 
immunised animals. Generation costs of antibodies 
from such a library are comparable to the generation 
of monoclonal antibodies by immunisation, but there 
is a significant benefit in time: while the generation of 
monoclonal antibodies requires several months, the 
selection of antibodies using a naïve recombinant 
library can be performed in a few weeks.
In the view of the expert panel, non-animal-derived 
antibodies are currently not used more frequently 
due to: a propensity toward existing methods; a 
lack of awareness of the current scientific status; 
perceived economic and contractual constraints; 
limited accessibility to entities producing such 
molecules; and significant scientific misconceptions.
In order to support higher scientific quality, meet 
ethical standards and ensure the limitations of 
animal-derived antibodies are overcome, it is 
recommended that the use of non-animal-derived 
antibodies is endorsed by government authorities, 
funding agencies and publishers. In conjunction with 
stringent validation and quality control, antibody 
reagents should be unambiguously identifiable by 
sequence. Furthermore, to ensure that scientific 
and ethical standards are met, the EU Governments 
could allocate subsidies to antibody producers or 
customers requiring custom antibody production, 
who satisfy eligibility criteria. Alternatively, or 
additionally, non-profit centres (akin to the academic 
animal facilities of today and the academic DNA 
synthesis and peptide synthesis facilities of the past) 
may provide such recombinant binder generation 
services to the community for a transition period, 
until the commercial sector takes over. To ensure 
researchers are incentivised, regulatory standards 
should also reflect the high quality scientific and 
ethical core values. If these commitments are 
made, scientists will be motivated to move away 
from animal-derived antibodies and be able to 
contribute to achieving the best possible scientific 
standards by making use of non-animal-derived, 
well characterised antibodies.
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1. Background
Antibodies are fascinating proteins characterised by 
their ability to identify and bind to specific targets 
of interest in very complex environments of other 
biomolecules (akin to finding the needle in the 
haystack). Therefore, they can be used to protect 
our health by detecting a vast range of molecules in 
health care management, biomedical research and 
development, consumer safety testing, product claims, 
cosmetics efficacy testing, or food and environmental 
contamination. Today, almost all antibodies in 
research are made by immunising animals. Antibodies 
can be isolated from most higher-order animals. For 
practical reasons, the majority of antibodies are made 
by immunising rabbits, drawing blood and collecting 
polyclonal antibodies from the serum. The other major 
portion is made by immunising mice, collecting their 
spleen cells and fusing them to cancer cells to create 
hybridomas secreting monoclonal antibodies (Figure 
1). They are then grown in cell culture to collect the 
tissue culture supernatant or from the ascites fluid 
of the peritoneal cavity of further mice (in countries 
where this is still allowed). Antibody genes from 
immunised animals can be subsequently cloned to 
allow recombinant expression. For example, Abcam 
lists over 10,000 antibodies as recombinant (https://
www.abcam.com/primary-antibodies/recombinant-
antibodies), mostly rabbit monoclonals. However, 
such methods always rely on an immunised animal 
to start with.
For more than 20 years, methods have existed to 
isolate antibodies from non-animal-derived libraries 
of antibody genes by purely biotechnological 
methods, e.g., from universal phage display libraries 
(Figure 1). No animals are used for this method. The 
EURL ECVAM Scientific Advisory Committee (ESAC) 
was requested to review the available evidence for 
the scientific validity of replacements for animal-
derived antibodies, used in research and diagnostics, 
generated using animal-free technologies. An ESAC 
working group was established comprising experts 
from academia and industry. Expertise within the 
panel covered antibody generation with animal and 
non-animal technologies, antibody engineering and 
antibody use in many immuno-analysis applications, 
and their use in different market sectors including 
diagnostics, therapeutics, research discovery and 
regulatory toxicity testing.
Figure 1: (Reprinted with permission from Breitling and Dübel, 1999, Recombinant Antibodies, © 1999, John Wiley & Sons) The 
three ways to generate polyclonal antisera, hybridoma-derived monoclonal antibodies and recombinant monoclonal antibodies. 
Recombinant antibodies are non-animal-derived, if no animals were immunised to obtain their encoding deoxyribonucleic 
acid (DNA). Recombinant antibodies can also be made from animal materials, by employing antibody gene repertoires from 
immunised animals for phage display or other in vitro selection methods, or by cloning of the antibody genes from hybridoma 
cells (dotted arrows).
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2. Definitions
Terminology related to animal-derived and non-
animal-derived methods, as they are used in the 
current report, are defined below.
Polyclonal antibodies (“polyclonals”) are either sera 
or immunoglobulin (Ig)-fractions collected from the 
blood of immunised animals (Figure 1). They are a 
collection of different immunoglobulin molecules that 
include a fraction reacting against a specific antigen 
of interest. Polyclonal antibodies typically react with 
several different epitopes of the antigen.
Monoclonal antibodies (“monoclonals”) are 
traditionally defined as being derived from the 
supernatant of hybridoma cells (see below). In theory, 
they contain a single antibody species from a single 
B-cell lineage but may be contaminated by additional 
antibody chains. An antibody sequence is typically 
not known but can be determined. Recombinant 
antibodies are also monoclonal, but in the scope of 
this report, the term “monoclonal” will be used to 
describe hybridoma-derived antibodies.
Hybridomas are artificial fusions between a 
myeloma cancer cell line and B-cells of an 
immunised animal producing one, or at most a few 
different antibodies. They are the production source 
of monoclonal antibodies.
Recombinant antibodies are produced by cells 
transfected with DNA encoding one antibody. 
Consequently, they are invariably sequence-defined 
and represent the best-defined type of affinity 
reagents with respect to specificity and unlimited 
availability, i.e., repeatability and reproducibility of 
experiments. Recombinant antibodies can be animal-
derived: generated by cloning the antibody encoding 
deoxyribonucleic acid (DNA) of hybridomas; or by 
cloning of antibody gene repertoires from B-cells 
of immunised animals. Recombinant antibodies 
can also be non-animal-derived: from “universal” 
antibody gene libraries generated by cloning the 
entire antibody gene repertoires of non-immunised 
(naïve) human donor B-cells or from completely 
synthetic genes.
Animal-derived antibodies – Includes any antibodies 
isolated or produced using methods where animal 
immunisation is required. This includes monoclonals, 
polyclonals and recombinant methods relying on 
immunised animals as starting material.
Non-animal-derived antibodies – Includes antibodies 
that were derived from in vitro recombinant libraries 
without the use of animal immunisation at any 
phase of library generation or antibody production. 
Such antibodies might be identical in structure to 
full-length immunoglobulin G (IgG), or they may 
encompass parts of an antibody such as fragment 
antigen-binding (Fab), single-chain fragment variable 
(scFv), single-chain fragment variable dimerised 
by the fragment constant (Fc) domain (scFv-Fc), 
disulphide-bond stabilised fragment variable (dsFv), 
camelid-derived variable heavy (VH) chain fragment 
(VHH), variable new antigen receptor (vNAR), etc. 
(some examples are given in Figure 2).
Non-antibody affinity reagents – Non-antibody 
polypeptides or oligonucleotides that bind to specific 
targets with high affinity. These technologies 
include a large variety of scaffolds, including, for 
example, designed ankyrin repeat proteins (DARPins), 
affibodies, anticalins, armadillo repeat proteins, etc. 
They are invariably produced from large synthetic 
libraries and thus not derived from animals.
Recombinant libraries are large collections of animal-
derived or non-animal-derived antibody genes, or non-
antibody affinity reagents. In this report, they refer to 
those not originating from immunised animals. They 
are the typical starting point for selection of non-
animal-derived antibodies or other affinity reagents. 
The antibody proteins are expressed from the 
library by using techniques such as phage, yeast or 
ribosome display. Libraries used in the generation of 
non-animal-derived antibodies from non-immunised 
sources are referred to as “synthetic”, “universal” or 
“naïve” to distinguish them from technologies that 
require immunisation of animals.
Antibody fragments are derived from 
immunoglobulin molecules and contain at least part 
of the antigen-binding site of an antibody (Figure 
2). Not all domains of a full-length antibody are 
necessary for antigen binding. The fragment variable 
(Fv) portion consisting of just the variable domains 
of heavy and light chain provide the entire antigen 
binding function, while the other domains provide 
effector function (e.g., binding to Fc receptors, 
antibody dependent cytotoxicity, opsonisation and 
complement determined cytotoxicity). There are also 
examples of antibody fragments consisting of only 
the single variable heavy (VH) domain that still show 
high specificity and sensitivity in antigen binding 
(Figure 2).
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Figure 2: (Reprinted with permission from Hentrich et al., 2018, Monoclonal antibody generation by phage display: History, 
state-of-the-art and future. In: Handbook of Immunoassay Technologies: Approaches, Performances and Applications, © 2018, 
Elsevier) Recombinant antibody formats. (A) Crystal structure of a full-length mammalian immunoglobulin (IgG) antibody. (B)-
(H): Schematic representation of different antibody formats. Domains are coloured as in (A) (B) Full-length IgG antibody where 
V=variable, C=constant, H=heavy, L=light, Fab=fragment antigen binding. Disulphide bonds are dark yellow. (C) Bivalent F(ab’)2 
(D) Monovalent Fab. (E) Single-domain antibody such as VHH. (F) Single-chain fragment variable (scFv). (G) scFv-Fc fusions are 
scFvs dimerised by the Fc domain. (H) Fab-A is with the fusion of alkaline phosphatase, that can be directly detected using a 
colorimetric substrate and is an example of a wide variety of tags that can be directly fused to the antibody fragment, pre- or 
post-selection.
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3. Scope
The ESAC working group was asked to provide a 
report on the scientific validity of the replacements 
for animal-derived antibodies used in current non-
therapeutic applications. These replacements could 
include both non-animal-derived antibodies and 
non-antibody affinity reagents at various stages 
of development and acceptance. The ESAC working 
group focused on non-animal-derived antibodies, 
since they are leading in respect of technological 
maturation and compatibility with the usual 
scientific applications, with large bodies of evidence 
supporting their use and fewest perceived hurdles 
to rapid implementation. It was noted, however, 
that there would be value in summarising non-
antibody affinity reagents as additional sources 
for replacement of animal-derived antibodies 
in this report and convening a separate working 
group to review them in greater depth. The use 
of non-animal-derived antibodies in therapeutic 
applications is well established.
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4. Current status of animal-derived antibodies
Polyclonal antibodies often have high overall 
antibody affinity against the target antigen, offering 
good sensitivity for detection of proteins that are 
present in low quantities in a sample. Polyclonals 
are inexpensive and quick to produce. However, 
since a polyclonal antibody represents a collection 
of antibodies from different B-cells that recognise 
multiple epitopes on the same antigen with a mixture 
of other antibodies to unknown antigens, only 0.5–
5% of the antibodies from the serum sample of 
an immunised animal bind to their intended target 
(Bradbury and Plückthun, 2015a). Consequently, high 
background is often observed. For example, this can 
be seen by the reactivity of the polyclonal serum used 
in a study by Russo et al. (2018) with the negative 
control. Immunopurification (chromatographic 
purification using the desired antigen as ligand) 
offers some benefit, if it is possible to immobilise the 
antigen in the correct steric orientation, i.e., when the 
binding site regions are not blocked by the chemical 
bonds introduced for immobilisation. Although 
unwanted polyclonal antibody specificity can be 
improved by such methods, the resulting antibody 
mixture still remains undefined in terms of epitope 
specificity, as the both composition of the mixture as 
well as the sequences of the individual antibodies 
are not known. Immunopurification is not usually 
done due to high cost and low yields.
More importantly, variability between different 
batches of polyclonals produced in different animals 
at different times presents a major obstacle to 
their reliability, such that even a particularly well-
performing batch may be difficult to reproduce by 
a subsequent immunisation. This batch-to-batch 
variability has inevitable consequences on the 
reproducibility of experiments that rely on polyclonal 
antibodies for protein detection.
As mentioned, polyclonals have a high potential for 
cross-reactivity due to multiple epitope recognition. For 
example, a lack of target specificity was identified for 
49 polyclonals against 19 different targets (subtypes 
of G-protein-coupled receptors) (Michel et al., 2009). 
Although technically possible (Cheung et al., 2012), 
there is no easy way to determine the sequences of 
the antibodies included in polyclonal sera.
Monoclonal antibodies (Köhler and Milstein, 1975), 
by contrast, are derived from a single antibody-
producing B-cell and therefore are thought to bind 
with high specificity to only one unique epitope, with 
reduced probability of cross-reactivity. Provided that 
the original clone remains available, it is possible to 
reproduce the original antibody. It is also possible 
to produce large quantities of identical antibody 
and routinely achieve batch-to-batch homogeneity. 
Monoclonal antibodies are significantly more 
expensive to produce than polyclonals (about ten 
times), requiring more time to produce and develop 
the hybridoma. Although it is possible to sequence 
the antibody genes of a hybridoma cell line, there 
are still only few monoclonal antibodies, with known 
sequences available for research applications.
Researchers are typically unaware that quite a 
number of hybridoma-derived monoclonal antibodies 
are actually not monospecific. Nonetheless, the 
literature is littered with reports of non-specific 
monoclonal antibodies. There are two fundamental 
reasons for their lack of specificity (see below for 
details): the particular antibody may react with more 
than one target molecule; and the hybridoma cell 
may contain additional antibody chains (Bradbury 
et al., 2018). By way of illustration, two widely used 
commercial mouse monoclonal antibodies against 
a master cell cycle regulator, cyclin-dependent 
kinase, were found to cross-react with a centrosomal 
protein due to partial overlapping amino acid 
sequence similarities between the epitope regions 
of the two antigens. This casts serious doubt over 
the findings of over 200 publications where this 
antibody has been used (Lukinavičius et al., 2013). 
In a 2008 study, fewer than half of around 6,000 
routinely used commercial antibodies (comprising 
both monoclonals and polyclonals) recognised only 
their specified targets (Berglund et al., 2008). A 2014 
study analysed 13,000 monoclonal and polyclonal 
antibodies in Western blotting and found that only 
45% of the antibodies yielded supportive staining 
(Algenas et al., 2014).
As mentioned, beside a potentially intrinsic lack of 
specificity, one other root cause is thought to be 
due to additional light chains from various origins, 
including the myeloma fusion partner, expression 
of more than one allele and in vitro evolution 
and fusion of more than one spleen B-cell to the 
partner cell line during hybridoma production. The 
presence of additional chains reduces antibody 
specificity and deteriorates the signal to noise ratio. 
In a study of 185 random hybridomas in a large 
multicentre study (seven labs from five countries), 
the lack of monospecificity was attributed to the 
genetic heterogeneity existing in a third (31.9%) of 
monoclonal antibodies (Bradbury et al., 2018).
As a consequence of the procedure employed for 
hybridoma generation, monoclonal antibodies raised 
in animals are vulnerable to such abnormalities, if 
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not sequenced and produced recombinantly. The 
resounding impact of using non-specific antibody 
reagents in terms of wasted cost, time and 
resources, as well as the repercussion on diagnosis 
and health management, is immeasurable and the 
true picture remains largely unknown. Whilst the 
reagents used in most clinical trials and especially 
in medical procedures cleared by the US Food and 
Drug Administration or the European Medicines 
Agency are extremely reliable, such abnormalities go 
largely unnoticed in cases where antibodies are not 
validated to the same degree.
To reiterate, a true monoclonal antibody (devoid of 
additional chains from the hybridoma) can still be of 
low specificity. Therefore, it is essential to subject any 
antibody and non-antibody affinity reagent to stringent 
quality control and validation, as described elsewhere 
(Bradbury and Plückthun, 2015a-c). The demands for 
specificity testing for animal-derived and non-animal-
derived antibodies and non-antibody affinity reagents 
are identical. The key difference is that recombinant 
products are molecularly defined and thus can be 
uniquely linked to the product properties.
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5. The current status of non-animal-derived antibodies
5.1 Formats
Antibody libraries for in vitro antigen selections can be 
generated from the activated B-cells of immunised 
animals (Krebber et al., 1997; Ridder et al., 1995; 
Muyldermans, 2001), from non-activated (naïve) 
B-cells to create naïve antibody gene repertoires, or 
from carefully designed “synthetic” repertoires (Yan 
et al., 2014; Knappik et al., 2000; Hust and Dübel, 
2004). Immunised antibody libraries are enriched 
for antibodies that bind a specific antigen but 
require that a new library be generated for each new 
antigen of interest. Such immune libraries have been 
constructed from virus-infected patients to isolate 
neutralising antibodies, as well as from cancer 
patients to isolate tumour specific antibodies (Geyer 
et al., 2012). Also, the great majority of VHH domain 
antibodies are created from immunised camelids, 
with subsequent library construction and phage 
display (see below).
An increasing number of different non-animal-
derived antibodies are in development, have been 
developed or are commercialised. They are generated 
independently of any living immune system and are 
available to replace animal immunisation techniques 
for a wide range of applications. Non-animal-derived 
antibodies are selected in vitro by phage, ribosome, 
yeast or cell display. Such libraries typically use the 
antibody scaffold, but there is an increasing list 
of publications where non-antibody scaffolds are 
used, generated either from nucleic acids or protein 
scaffolds into which diversified loops are inserted 
to form the antigen binding site (Skerra, 2007), or 
other diversification strategies have been used (see 
Section 8).
Non-immunised or synthetic “universal” libraries 
contain an enormous repertoire (typically more than 
1010) of different candidate antibody genes. This 
equates to structural diversity of antibodies that is 
equal to or even larger that of any naïve immune 
system prior to affinity maturation and thus provides 
similar or even better chances to identify a specific 
binder against any target antigen (Bradbury et al., 
2011). Once such a library is established, it can be 
used for decades and replaces a lifetime supply of 
immunised animals.
The recombinant antibodies isolated from the 
libraries can be converted into any antibody format, 
including IgG, the essential function being centred on 
the binding region in a supporting framework region. 
Consequently, various less-bulky antibody formats 
have been developed, compatible with bacterial 
expression systems (Figure 2). For example, the 
approved therapeutic antibody drug blinatumomab 
is solely composed of two scFv fragments fused by 
a linker peptide. The antibody drugs ranibizumab and 
certolizumab pegol are Fab fragments (see IMGT at 
http://www.imgt.org/mAb-DB/query; or DrugBank at 
https://www.drugbank.ca/).
A particular comment is needed for nanobodies 
(derived from camelid VHH domains), as the 
overwhelming majority is still obtained by immunising 
llamas or camels; yet only recently, synthetic 
libraries have been reported that appear to perform 
equivalently (Crepin et al., 2017; Moutel et al., 2016; 
Yan et al., 2014) and can avoid the immunisation of 
animals. Many nanobodies have long protruding loops 
and may thus be suitable to access cavities in targets. 
In general, they are less aggregation prone than scFv 
fragments, particularly those of murine antibodies, 
making some fusion proteins easier to produce.
Synthetic “universal” libraries have been mostly 
built using human antibody sequences as blueprint, 
as the intention was mostly to develop human 
antibody therapeutics. There are some examples for 
libraries built on non-human antibody scaffolds (e.g., 
Sommavilla et al., 2010; Moutel et al., 2016; McMahon 
et al., 2018) but there are no known limits concerning 
the choice of species for building such libraries.
5.2 Principles of Action
Antibodies can be selected by a variety of methods 
(Bradbury et al., 2011). Here, we focus on phage 
display (Figure 3), the most widely adopted system, 
the development of which was honoured with the 
Nobel Prize in 2018.
The design of a non-animal-derived antibody universal 
phage display library and selection of binders from it 
adopts and adapts the same mechanistic principles 
of nature that have been relied upon to produce 
animal-derived antibodies, prior to and following 
immunisation, thereby mimicking and surpassing 
the whole animal immune response through the 
careful control of in vitro parameters (Fuchs et al., 
1992). These include: combinatorial diversification to 
create the hypervariable binding regions; selection 
of antibody-antigen binding partners; potential 
counterselection against antigens that should not be 
cross-reactive; and optional affinity maturation for 
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improved sensitivity (Figure 3). In consequence, these 
mechanisms create at least the same repertoire, 
diversity, structure and function as is achieved by 
using immunised animals.
The principle of combinatorial diversification, 
otherwise known as recombination of variable (V), 
diversity (D) and joining (J) segments is relied upon 
by nature, pre-immunisation, to create a theoretical 
diversity of at least 1012 potential antibody gene 
sequences (Alberts et al., 2002). The number of 
peripheral blood B-cells in a healthy adult human is 
in the order of 5 × 109 (Briney et al., 2019). Using 
the same principle of combinatorial diversification 
for in vitro antibody library construction, genetic 
sequences of antibody binding regions are manually 
re-combined (synthetic) or amplified from B-cell 
isolated DNA derived from human blood (non-
activated B-cells), using standard molecular, cell 
and micro-biology techniques. The genetic sequence 
of billions of different polymerase chain reaction 
(PCR) amplified antibody genes, with high diversity 
in the binding regions, are subsequently cloned 
into a phagemid vector (Breitling et al., 1991) and 
fused to filamentous phage minor coat protein gene 
III, which ensures that antibodies will eventually be 
expressed on the surface of a phage particle, fused 
to a phage coat protein and thereby exposed for 
antigen recognition. Introduced into a laboratory 
strain of the Escherichia (E.) coli bacterial host, a 
universal antibody DNA library of the chosen format, 
e.g., scFv or Fab, is created, with diversity only 
limited by the transformation efficiency of E. coli. 
This has yielded libraries with over 1011 independent 
transformants (CAT2 library, Lloyd et al., 2009; 
Ylanthia® library, Tiller et al., 2013). Infecting the E. 
coli culture with helper phages leads to production 
of phages that carry the antibody on their surface 
and the corresponding antibody gene information in 
the packaged phagemid, thereby linking the antibody 
genotype with its phenotype. The phage particles can 
be harvested and used for the isolation of specific 
antibodies by phage display panning (Schirrmann et 
al., 2011; Barbas et al., 1991; Altshuler et al., 2010).
Once a phage display library is constructed and the 
antibodies expressed as proteins, selecting the right 
antibody to bind to the antigen from the enormous 
repertoire of possible antibody binding sites might 
seem a daunting prospect, analogous to searching 
for the needle in the haystack. In fact, this selection 
process also resembles that which takes place in 
nature and the practice of isolating antibodies secreted 
by hybridomas. For animal-derived monoclonal 
Figure 3: (© 2020, Dϋbel under CC BY 4.0) Antibody phage display.
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antibody production, a B-lymphocyte population, 
enriched by cells secreting antibodies to the target 
of interest (or antigen), is isolated from the spleen 
of immunised animals and fused with myeloma cells 
to produce an immortal hybridoma cell. Each cell will 
(in theory) only secrete identical antibodies specific 
for one epitope. Antibody candidates are selected by 
detection of antigen-bound secreted antibodies from 
each cell with the immobilised antigen, and positive 
clones are subsequently expanded in tissue culture 
or in the ascites fluid of the mammalian peritoneal 
cavity (Nelson et al., 2000). In phage display, the vast 
collection of phages displaying the antibodies encoded 
in the library is brought in contact with the (immobilised) 
antigen of interest. The antibody-carrying phages 
that show affinity to the antigen are captured and 
the non-specific phages are washed off, a process 
referred to as “panning”. Finally, the bound phages, 
containing the corresponding genetic information for 
the displayed antibody, are eluted and used to infect 
new E. coli cells. The infected E. coli culture is grown to 
produce new copies of the antibody-displaying phages 
that were eluted in the previous panning round. After 
typically 3 rounds of panning, the enrichment of 
phages displaying antibodies that bind to the target of 
interest is so strong that individual phage-infected E. 
coli cells can be identified and isolated. Positive cells 
are grown to express antibody fragments such as 
scFv or Fab (mono- or bivalent), or the antibody genes 
are re-formatted to, for instance, IgG or scFv-Fc and 
produced in mammalian cell culture.
The immune system has evolved cellular machinery 
for selecting those binding specificities that are 
needed to meet the challenge of an invading antigen, 
specifically amplifying those antibodies until they 
become prevalent in the total antibody population 
(Petrenko and Smith, 2000). Non-animal-derived 
antibodies have all the target recognition qualities 
of animal-derived antibodies. In vitro selection of 
the phage-displayed antibody against the desired 
antigen similarly interrogates the functionality, i.e., 
affinity and stability of potential binding partners, 
which can be selected for under increasingly stringent 
conditions such as competition with closely related 
antigens, pH or concentration. The specificity can 
then be tested and verified.
In nature, during the course of a host’s immune 
response, the antibody affinity to the antigen 
continues to increase due to somatic hypermutation 
focusing on the hypervariable, antigen-binding region 
of the antibody genes, followed by competitive clonal 
selection. Similar mechanisms have been developed 
for affinity maturation of antibodies obtained from 
naïve or synthetic recombinant libraries. These 
include designed or PCR-based random mutagenesis, 
or variable chain shuffling to name a few. They 
generate a vast repertoire of antibody variants 
from the starting clone (or clones), which are then 
used as starting point for high-stringency selection 
procedures to enrich for high-affinity variants 
(Teng and Papavasiliou, 2007; Roskos et al., 2007). 
Improvements in other antibody characteristics such 
as stability, pharmacokinetic parameters, effector 
parameters, tissue penetrating capacity of antibodies 
and their immunogenicity are possible (Altshuler et 
al., 2010; Igawa et al., 2011) by carefully adjusting 
the in vitro selection conditions (see Section 7). 
While affinity in immunised animals is thought to be 
limited to ~100 picomolar (pM) by the physiological 
mechanisms of B-cell activation, in vitro generated 
affinities in the low pM range can often be achieved 
(Batista and Neuberger, 1998; Zahnd et al., 2004; 
Luginbühl et al., 2006; Geyer et al., 2012).
5.3 Antibodies used in typical laboratory 
immuno-analysis applications
The main immuno-analysis applications used 
today are Western blotting, immunohistochemistry 
(IHC), immunocytochemistry (ICC), flow 
cytometry, immunosorbent assays (ELISA) and 
immunoprecipitation (Uhlen et al., 2016). Other areas, 
such as multiplexed planar or bead arrays are mostly 
based on the ELISA or fluorescence principle. Non-
animal-derived antibodies have been generated and 
used in all those applications (Borrebaeck, 2017). In 
some publications, direct comparison of non-animal-
derived antibodies with animal-derived antibodies 
in typical immuno-analysis applications, has been 
performed. In addition, affinity ligands obtained from 
scaffold libraries have found additional applications 
in affinity purification because of their inexpensive 
production, robustness and wide resistance to a 
range of pHs, all of which are desired properties for 
column regeneration and immobilisation processes 
(Yu et al., 2017; Hansen et al., 2017). Furthermore, 
smaller non-animal-derived antibodies such as 
nanobodies or affinity ligands obtained from scaffold 
libraries have been frequently generated for super-
resolution microscopy (Pleiner et al., 2015). For in vivo 
imaging applications, they have been found useful 
as the smaller size leads to high tumour uptake and 
shortens in vivo half-life due to fast renal clearance 
and therefore improves signal-to-background ratios 
(Helma et al., 2015; Bedford et al., 2017). The 
availability of sequences enables the site-specific 
conjugation of labels in these cases, which is another 
advantage (Jost and Plückthun, 2014). Some of the 
affinity ligands have progressed to late stage clinical 
trials for therapy (for clinical trials numbers, see 
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Section 8 below). They have also been used in various 
diagnostics applications, although their clinical use 
in routine applications still awaits validation. Some 
examples for use of non-animal-derived antibodies 
in the main research applications are given below.
For Western blotting, a direct comparison between 
conventionally produced and non-animal-derived 
antibodies for a set of proteomics targets had been 
performed by Ohara et al. (2006). The authors 
concluded that non-animal-derived antibodies are 
well suited for Western blot analysis and compare 
favourably with the polyclonal antibodies used in 
this study regarding sensitivity and specificity. Other 
laboratories have reported Western blotting results, 
using non-animal-derived antibodies or aptamers 
to be comparable or superior to blots probed with 
traditional antibodies (Cho et al., 2011; Lazzarotto 
et al., 1997; Martin et al., 2013; Ramos et al., 2007, 
2010; Shin et al., 2010; Webber et al., 2014). As 
mentioned below (see Section 6.5), the traditional 
polyclonal secondary antibodies can be replaced as 
well (Pleiner et al., 2018; also see https://abcalis.
com/multiclonals).
Antibodies that work in IHC staining of formalin-
fixed paraffin-embedded (FFPE) tissues are generally 
difficult to generate, as the cognate antigen undergoes 
massive modification during formalin-fixation. Using 
in vitro antibody selection processes, such as phage 
display, FFPE tissue can be used directly for selection 
of antibodies. There are several examples in the 
literature where phage display antibody selection has 
been successfully performed for generation of IHC-
positive non-animal-derived antibodies (see Figure 
8, see Section 7.3). For instance, a differential guided 
selection against mantle-cell lymphoma FFPE tissue 
sections with depletion on normal human tonsil 
tissue yielded IHC positive antibodies for vimentin 
(Jarutat et al., 2007). Protocols for this method 
have been published (Haaf et al., 2018). Similar 
methods have been applied to select non-animal-
derived antibodies for staining of fresh frozen tissue 
sections. Using a peptide antigen comprising the 
epitope of the well-characterised Ki-67 antibody led 
to the generation of non-animal-derived antibodies 
that performed well in IHC on FFPE tissue sections, 
showing a Ki-67 equivalent staining pattern (Jarutat 
et al., 2006). Comparison of non-animal-derived 
antibodies with polyclonal antibodies generated 
against the same antigens and testing in IHC has 
also been investigated (Ohara et al., 2006). While 
the polyclonal antibodies mostly showed various 
extents of non-specific binding on the analysed 
tissues, the non-animal-derived antibodies could 
be used to specifically detect the proteins in brain 
and other tissues. Use of affinity ligands obtained 
from scaffold libraries have also been explored in 
IHC, exemplified by DARPins (Theurillat et al., 2010; 
Boersma, 2018) or affimers (Bedford et al., 2017). 
An anti-human epidermal growth factor receptor 2 
(HER2) affibody is today commercially available for 
use in IHC (Bedford et al., 2017).
Flow cytometry is another main immuno-analysis 
application that is highly dependent on antibodies. 
These reagents are typically directed against a 
cell surface marker and are labelled with different 
fluorescent dyes. Non-animal-derived antibody 
generation, using either purified antigen or whole 
cells in differential panning set-ups have been 
described. Antibodies for flow cytometry may bind 
to cellular Fc-receptors, thereby creating background 
staining. The recombinant nature of non-animal-
derived antibodies can provide a solution by either 
producing the antibodies without the Fc part or 
by including mutations that suppress Fc-receptor 
binding (LALA, TM, or N297A mutations), which have 
been investigated on human antibody Fc regions but 
can also be transferred to other species (Hentrich 
et al., 2018), demonstrating the versatility of non-
animal-derived antibodies (Vincent and Zurini, 2012; 
Liu et al., 2017; also see https://absoluteantibody.
com/antibody-resources/antibody-engineering/fc-
engineering/). Scaffold proteins such as DARPins can 
be efficiently expressed in bacteria directly as green 
fluorescent protein (GFP) fusions and thus used directly 
in flow cytometry, also in identifying cell-binding and 
overlapping epitopes (Andres et al., 2019).
Antibodies are also commonly used for 
immunoprecipitation to capture proteins from their 
cellular environment to identify binding partners 
or post-translational modification. Non-animal-
derived antibodies have been generated for use in 
immunoprecipitation experiments (Colwill et al., 
2011). The study concluded that non-animal-derived 
antibodies were able to capture proteins from cell 
lysates, similar as animal-derived antibodies. In 
another study, non-animal-derived antibodies 
were generated against peptides to three proteins, 
empirically determined as proteolytic fragments 
observed by mass spectrometry, to be used as capture 
reagents in multiple reaction monitoring (MRM) 
experiments (Whiteaker et al., 2014). The resulting 
antibodies were tested in both Fab and IgG formats 
and compared to high-affinity monoclonal benchmark 
antibodies from mouse or rabbit generated against 
the same peptides by immunisation. The performance 
of the non-animal-derived antibodies in the immuno-
MRM application was found to be excellent.
A special form of immunoprecipitation is the chromatin 
immunoprecipitation (ChIP) application, in which 
antibodies binding to posttranslational modification 
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of histones are used. Non-animal-derived antibodies 
have been generated against a trimethylated lysine 
residue of histone H3 (H3K9me3) by Hattori et al. 
(2013). The authors first tested eight commercial 
animal-derived antibodies against this target and 
found all but one to be of poor quality. The only one 
with good quality was a polyclonal antibody lot that 
was no longer available. Therefore, they selected 
and affinity-matured an antibody from a universal 
library, which showed excellent performance in 
ChIP. In addition, they created a negative control by 
mutating four key residues of this antibody (Hattori 
et al., 2013). This antibody is commercially available 
(Diagenode, product C15500003).
Non-animal-derived antibodies have been generated 
for producing antibody arrays, which are used to 
measure and quantify multiple biomarkers in parallel. 
A microarray platform composed of 349 non-animal-
derived antibodies formatted as single-chain variable 
fragments (scFvs) directed against 156 antigens 
has been published (Mellby et al., 2018). It was 
successfully used to identify a biomarker signature 
associated with pancreatic stage I/II cancer, useful for 
early detection in cancer patients. For building high-
density antibody arrays, non-purified probes are to 
be directly purified, oriented and coupled in a generic 
one-step procedure directly on the chip (Steinhauer 
et al., 2006). Here again, the recombinant nature of 
non-animal-derived antibodies enables site-directed 
addition of affinity tags, such as the His- or Myc-tag 
for affinity capture of non-animal-derived antibodies 
to the chip surface (Steinhauer et al., 2006). Other 
array formats such as multiplexed bead arrays 
typically use antibody sandwich pairs for analyte 
quantification. During both animal-derived and 
non-animal-derived antibody generation, the initial 
screening of candidate clones is most often done in 
ELISA format due to the high throughput that this 
assay allows. Sandwich pairs are then identified in a 
second screening step, whereby positive antibodies 
from the first screen are tested one by one for their 
ability to build sandwich pairs. In vitro selection 
methods, such as phage display, enable guided 
selection strategies with the aim of selecting a 
matching detection antibody to a complex of antigen 
bound to a capture antibody (Hentrich et al., 2018).
5.4 In vitro diagnostics and other 
applications
Non-animal-derived antibodies are commonly 
used in commercial in vitro diagnostic assays, 
both as active components of the immunoassay 
or as controls and calibrators. Some of the distinct 
advantages that they can offer in this area are 
exemplified below.
As non-animal-derived antibodies are often derived 
from human antibody libraries, they can be used 
as alternative to human disease state sera, as 
the calibrator material. Sera can be replaced by 
recombinant phage display antibodies with the 
desired specificity and reformatted to the human 
isotype of choice (Hentrich et al., 2018). A major 
challenge with serological testing is access 
to consistent and unlimited control reagents 
to provide assay quality control and facilitate 
data consolidation. Often clinical positive sera 
are difficult to source and use as routine, inter-
laboratory reagents. It has been demonstrated that 
non-animal-derived antibodies are suitable control 
reagents for serological and autoimmune testing 
(Knappik et al., 2009, Golden et al., 2016).
The ability to perform in vitro selection on antigen 
complexes has been used to develop non-animal-
derived antibodies that are difficult to obtain by 
animal immunisations. A highly specific antibody 
against the complex formed between an anti-
morphine antibody and morphine was selected from 
a naïve scFv phage display library (Pulli et al., 2005). 
The complex-specific antibody was subsequently 
used in a fluorescence resonance energy transfer 
(FRET) assay to detect morphine bound by the anti-
morphine antibody, thereby avoiding the competitive 
ELISA format that is typically used in immunoassays 
for the detection of small compounds. Such an assay 
can avoid the problem of false positive results that 
can arise from the use of a competitive assay format. 
Another recent application of this selection strategy is 
the generation of highly specific non-animal-derived 
antibodies that bind to a complex of antibody drug 
bound to the drug target (Harth et al., 2018). Such 
specificities are used in pharmacokinetic studies 
during development of antibody therapeutics, as 
they enable quantification of human antibody drugs 
in serum samples without using the complicated 
bridging assay format.
Other advantages of non-animal-derived antibodies 
are evident from the sections above: they allow 
consistent, reproducible and sustainable supply; 
assay conditions can be taken into account by 
adaptation of the in vitro selection process; and 
the selection of stable antibodies is possible. For 
instance, the prolonged incubation at 37°C or 
repeated cycles of treatment with highly chaotropic 
guanidine hydrochloride was used to select scFvs 
with high stability for the detection of C-reactive 
protein (CRP) incorporated into a lab-on-a-chip 
system as a point-of-care device to rapidly detect 
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the acute phase of bacterial-induced inflammation 
(Al-Halabi et al., 2013). A stable recombinant 
scFv-Fc construct allowed the development of a 
sandwich-ELISA, integrated on a biosensor portable 
device, to monitor Legionella concentration in water 
for human use, as a rapid on-site alterative to the 
standard detection approach that relies on lengthy 
cultivation and analysis of bacterial cultures (Kuhn 
et al., 2017). The possibility of affinity maturation 
for increased assay sensitivity and the realisation 
of large multiplexed assay concepts (Borrebaeck, 
2017) is to mention but a few of the capabilities 
of non-animal-derived antibodies, since they are not 
dependent on the antibodies that an animal decides 
to generate.
5.5 Validation of large data sets 
exemplifying the performance of non-
animal-derived antibodies in different 
applications and from various sources
Although there is no accepted standard for the 
provision of data to clarify the performance 
characteristics for an antibody-antigen interaction, 
attempts have been made to codify the minimum 
information required for antibody performance 
(Gloriam et al., 2010; Uhlen et al., 2016). Nonetheless, 
adoption of such proposals has been slow, and 
information on antibodies tends to be generated on 
an ad hoc basis. Data may therefore be supplied by 
various immuno-analysis techniques. Evidence of 
the antibody-antigen binding characteristics typically 
provided in commercial catalogues includes the visual 
identification of a pattern of localised tissue staining 
(IHC), or the identification of a target at the expected 
molecular weight under reducing conditions (Western 
blotting). These are not statistically quantifiable 
measurements. Alternatively, a modification in the 
expression of a molecule can be marked by the 
intensity of fluorescence or enzymatically induced 
colour change marker, conjugated as a tag to the 
antibody and compared to an off-target negative 
control (ELISA). Often, this approach is used as 
the primary screen for identifying positive clones 
in antibody development, after several rounds of 
panning using universal recombinant libraries or 
following animal immunisation and extraction of 
B-cells. The initial screen is a routine procedure to 
eliminate non- or low-specificity monoclonal binders 
and is performed for all monoclonal antibodies, 
regardless of their source (animal or non-animal-
derived). Selection produces high numbers of clones 
of varied specificity and affinity. At this stage, 
duplicate sequences and clones that do not meet the 
set criteria can be eliminated.
It is important to understand that the performance of 
an antibody in one application may bear no relation to 
its performance in another. This is primarily due to the 
fact that some assays require an obligate denatured 
state (Western blots), others an obligate native 
state (Fluorescence-activated cell sorting; FACS), 
others are dependent on the imposed experimental 
conditions (IHC), yet others can be adapted (ELISA). 
In aggregate, this means that this can render data 
difficult to compare outside of a consistent quality 
control framework that would otherwise serve to 
facilitate comparisons of antibodies from different 
sources for use in different applications.
Several large-scale antibody generation studies 
have met this challenge by providing large data 
sets, using quantifiable methods of analyses such as 
the rate constant of association (kon), rate constant 
of dissociation (koff), or equilibrium dissociation 
constant (KD) of a binding partnership as measure 
of affinity, e.g. determined by surface plasmon 
resonance (SPR) analysis. Affinity data may also 
more crudely be determined by ELISA determination 
of the antibody concentration at which binding is 
detected, or by the mean fluorescence intensity (MFI) 
following analysis of the flow cytometric localisation 
of binding to a single cell target. Some data sources 
may even identify the specific epitope employed 
(epitope mapping). Importantly, the performance of 
the antibody is not only defined by favourable affinity 
to its target, but also by recognition of the target 
modified during the specific application, and by the 
lack of significant interaction with other substances 
that may interfere in the relevant assay, all of which 
have to be tested independently.
Examples are cited throughout the report giving 
detailed analyses of non-animal-derived antibodies 
performing in all known immuno-analysis 
applications. Additionally, a selection of data has been 
extracted from published sources to demonstrate 
the feasibility of their generation in large numbers. 
Further, evidence of their development for clinical use 
is included. The data examples are derived from a 
range of different phage display library sources, from 
various countries and different antibody formats (see 
Appendix, Section IV).
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6. Why are non-animal-derived antibodies not already being used more 
frequently?
Major barriers to the uptake of non-animal-
derived antibodies exist that have impacted on the 
evolution of antibody development and account 
for the erroneous beliefs that have hindered their 
widespread use. These include: a propensity toward 
existing methods; a lack of awareness of the 
current status; perceived economic and contractual 
constraints; limited accessibility to resources; and 
significant scientific misconceptions.
6.1 Propensity for existing methods
Many researchers consider the problems that they 
experience with catalogue antibodies (see Section 
4 and Goodman et al., 2018) as unavoidable, 
i.e., a molecular feature of antibodies in general. 
This misconception arises from the day-to-day 
experiences of most researchers using catalogue 
antibodies and the widespread use of polyclonal 
antibodies that show the greatest specificity 
problems. Monoclonal antibodies can also suffer 
specificity issues (see Section 4) although they 
are generally better. The question arises as to why 
researchers continue to use antibodies that are so 
problematic. This was addressed by Bradbury et al. 
(2011) who concluded that researchers are generally 
unaware of recombinant ways to make antibodies, a 
problem reinforced by the lack of companies providing 
recombinant antibody selection services for the non-
therapeutic market, and scientific misconceptions 
on the quality of antibodies generated by display 
methods which reflect early experiences in the field.
The generation methods for animal-derived antibodies 
have not significantly improved in response to these 
known issues over the past 40 years, nor have they 
been rigorously quality-controlled in light of the above 
problems. As a result, there is a perception that these 
problems are inherent to antibodies in general and 
that their shortcomings must be accepted. It would 
therefore stand to reason that a different method of 
making antibodies would not improve the outcome. 
However, the unique advantages of recombinant 
antibodies, such as being sequence defined, has been 
reported in high-profile papers so there is a solid 
body of data to amend this perception.
6.2 Lack of awareness
Recombinant antibodies can be produced by cloning 
the DNA of animal-derived hybridomas (Bradbury et 
al., 2018), obtaining B-cell repertoires from immunised 
animals (Krebber et al., 1997, Ridder et al., 1995, 
Muyldermans, 2001), or creating completely animal-
free synthetic (Knappik et al., 2000; Tiller et al., 2013; 
Säll et al., 2016) or naïve human B-cell universal 
libraries (Hust and Dübel, 2014; Mondon et al., 
2008). During the early years (1990’s), recombinant 
antibodies were typically cloned from hybridomas. 
Despite optimism in the scientific community, there 
were difficulties in producing some of the clones 
as scFv fragments (see Figure 2) in bacteria, using 
the newly developed systems of the day. Further, a 
fraction of these hybridoma-derived scFv fragments 
were unstable proteins - an inherent property of 
some of the mouse variable domains (Wörn and 
Plückthun, 2001). Thus, these scFv fragments were 
not user-friendly, i.e., they could not be used in typical 
applications without additional effort and know-
how. Furthermore, users needed to be educated that 
detection had to be achieved by using an anti-tag 
antibody and not by an anti-Fc polyclonal antibody 
— since they lacked an Fc region. Even though the 
detection would ultimately be identical (typically, 
by a linked enzyme or fluorophore to the detection 
antibody), there was the perception that the polyclonal 
anti-Fc serum would result in higher sensitivity.
In addition, some companies sold premature products 
and commercial kits that did not work, which added 
to the negative image. Furthermore, early antibody 
libraries did not produce antibodies with affinities as 
high as those derived from immunisation and the 
problems with mouse scFv protein stability resulted 
in a perception bias against display methods of 
antibody generation that has persisted despite 
twenty-five years of development and maturity.
Today, recombinant antibodies can be generated 
with superior properties and their properties can 
further be improved by in vitro evolution after initial 
generation (see Section 9). Still confusing for many 
users, however, are the larger number of possible 
recombinant antibody formats. While most animal-
derived antibodies are in the IgG format, recombinant 
technologies offer additional opportunities to 
generate a variety of formats, a few of which are 
depicted in Figure 2 (see Section 2). Often overlooked 
is the fact that recombinant antibodies can easily be 
made also as full-length IgG, giving rise to parameters 
that render them functionally indistinguishable from 
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animal-derived IgGs in all typical applications, with 
the added benefit of sequence identity (see Section 
8) preserving their monospecificity and unlimited 
supply. In certain applications, the use of antibody 
fragments instead of full-length IgG is an advantage.
The IgG molecules used as approved therapeutics - 
the application with the highest quality standards - 
are stably produced in large amounts and are now 
exclusively recombinant. Some of the approved 
therapeutics have been made using animal-free 
methods, while about half have been derived from 
immunised mice and then “humanised”. Several 
marketed therapeutic antibodies take advantage of 
smaller formats such as the Fab or the scFv format.
To address educational needs, an abundance of 
different approaches to non-animal-derived antibody 
generation and selection methods are described 
in the literature including reviews, methodologies 
and research, indicating that sufficient educational 
resources exist. A simple PubMed analysis (Figure 
4) reveals that an abundance of publications exists, 
indicating that there is no shortage of learning 
opportunities. A wealth of literature describing the 
shortcomings of animal-derived antibody approaches 
also exists (for example, see Couchman 2009). 
However, the scientific community would benefit from 
a greater focus on training and education to improve 
competency. Not every laboratory is familiar with 
modern molecular cloning and selection technologies 
and only very few institutions have a service facility. 
In contrast, animal houses are easily accessible and 
the cell culture work for making hybridomas is more 
familiar to biology laboratories.
6.3 Perceived economic and contractual 
constraints
In the past, few companies provided the necessary 
resources to produce non-animal-derived antibodies 
for the non-therapeutic market. Although this was 
perceived as lack of utility, this was more related 
to the attraction of the more lucrative therapeutics 
market to this sophisticated technology and thus 
driven by investment opportunities. Consequently, 
non-animal-derived antibodies were simply not 
available, neither off-the shelf nor custom-made 
(with very few exceptions). In addition to the 
focus on the therapeutics market, IP restrictions 
prevented more widespread commercialisation of 
the technology. Highly publicised patent fights in the 
therapeutic/pharma world, regarding recombinant 
antibody generation platforms and the exorbitant 
price tags of company deals, gave the impression 
that the technology was challenging, exclusive and 
very expensive, creating economic and contractual 
constraints. However, all initial recombinant antibody 
generation patents have now expired in the EU, 
making the technology available to all.
Although initial naïve recombinant library 
development requires a significant time investment, 
once the library is developed, this supplies a diversity 
of antibody candidates equivalent to a lifetime supply 
of animals and abolishes the ongoing cost of animal 
care. Generation costs of monoclonal non-animal-
derived antibodies are similar to, or even cheaper 
than, those of monoclonal animal-derived antibodies 
because they are faster and only require standard 
laboratory equipment and consumables. This clearly 
underlines that antibody selection from universal 
libraries can replace animal use in this competitive 
market. As demand increases, technologies are 
expected to improve and further price reductions 
are anticipated. Beside cost, there is a significant 
benefit in time. While the generation of monoclonal 
antibodies needs several months, the selection of 
antibodies using a naïve recombinant library can be 
performed in a few weeks.
Polyclonal antibodies not only represent the 
largest fraction of commercially available research 
antibodies, but also are typically chosen by budget-
restrained researchers over monoclonal reagents 
because of their significantly lower generation cost 
(currently about one tenth of a hybridoma antibody). 
However, as mentioned above, polyclonals are often 
problematic in terms of specificity and reproducibility.
At an annual worldwide spend of $1.6 billion on the 
antibody market and with only 5-49% functionality 
being reported in monoclonal reagents alone, a 
staggering annual loss to the biomedical research 
community of up to $800 million for the purchase 
of non-functional antibodies alone is estimated. The 
use of non-specific and poorly defined antibodies 
elicits an additional and unaccounted for waste 
in materials, time, money and follow-on research 
(Bradbury and Plückthun, 2015a; 2015c).
6.4 Limited accessibility to resources
Due to a lack of awareness, contractual constraints 
and a subsequent lack of demand, as well as lower 
profit margins, few companies have been motivated 
to invest in or market recombinant antibodies and 
affinity reagents other than for the therapeutics 
market. Fortunately, that situation is changing and 
some companies are now generating non-animal-
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Figure 4: (© 2020, Gray under CC BY 4.0) Graphs showing a) the annual and b) the cumulative number of publications 
(1991 to present), for the recombinant antibody formats described in Figure 2, and scaffolds, using search terms: phage 
display OR ribosome display OR yeast display. Scaffolds included DARPin(s) or Designed Ankyrin Repeat Protein(s), monobody/
ies, affilin(s), affitin(s), avimer(s), fynomer(s), FN3, cystine knot(s), abdurin or adhiron, affimer, adnectin, affibody, anticalin or 
lipocalin, bicyclic peptide or macrocyclic peptide or peptide macrocycle, or dipeptide.
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derived research antibodies for customers (see 
Appendix, Section V). However, it is important to be 
aware that some companies may offer recombinant 
antibodies advertised as “animal free” that were 
actually originally derived from animal sources, i.e., 
derived from hybridomas or libraries obtained from 
immunised animals, e.g., http://www.enzolifesciences.
com/browse/products/by-product-type/antibodies/
recombinant-antibodies/.
Recombinant antibodies made entirely by non-
animal methods are viable products in the research 
reagent market (see Appendix, Section IV and Section 
V). There are even examples of non-animal-derived 
research antibodies in catalogues that were made 
explicitly by phage display due to the inability to 
obtain antibodies with the required sophisticated 
functionality by animal immunisation, with some 
even sold as if they were derived by immunisation. 
Examples of such specificities include the anti-
DJ-1 antibody AbD03055 that recognises the DJ-1 
protein only when oxidised at cysteine residue 106, 
whereby the oxidative state at C106 determines the 
biological activities of DJ-1. The antibody has been 
selected from a recombinant library using a peptide 
comprising the oxidised cysteine 106 for selection 
and simultaneously blocking the library with a peptide 
of the same sequence but containing a reduced 
cysteine 106 (Ooe et al., 2006,). Another example 
is the anti NS2B-NS3 antibody AbD05320 that 
inhibits the active site of the NS2B-NS3 proteinase 
from West Nile Virus. Here the recombinant library 
was blocked with a mutant NS2B-NS3 construct 
in which a histidine residue had been replaced by 
alanine within the NS2B-NS3 active site (H51A). This 
substitution mutation only altered the active site, 
keeping all other putative epitopes of the wild-type 
enzyme intact. Hence the mutant could be used to 
block members of the antibody library that bind to 
epitopes outside the active site (Shiryaev et al., 2010). 
Another example is the anti-human SMAD3 antibody 
ABC0204 obtained by phage display panning using 
competition with the non-phosphorylated epitope to 
select antibodies that recognise a single epitope only 
if this is phosphorylated (Blokzijl et al., 2016).
It is also largely unknown that thousands of non-
animal-derived recombinant antibody reagents 
have successfully been made and used in academic 
consortia (see Appendix, Section III).
Additional research areas that could be enabled (see 
Section 7) by recombinant antibodies require that 
the user can obtain the DNA of the antibody from 
the company that generated the antibody. Such 
applications include fusion on the surface of cells, 
e.g., chimeric antigen receptors on T-cells (CAR-T 
cells), for redirecting viruses, or for studying cell 
biology with intrabodies, to name a few examples (see 
Section 7.5). However, even among the companies 
that generate antibodies by display methodologies, 
very few make the DNA available for free. As long as 
this is the case, non-profit organisations or consortia 
(see Section 9) still have an important role to play.
6.5 Scientific misconceptions
An important source of scientific view-points on 
the reliability of non-animal-derived antibodies are 
expressed in the publicly available Non-Technical 
Project Summaries under Article 43 of Directive 
2010/63/EU (EU, 2010) on the protection of animals 
used for scientific purposes (http://ec.europa.eu/
environment/chemicals/lab_animals/nts_en.htm), 
produced by each Member State. Opinions have also 
been collected through LinkedIn forums and personal 
discussions with users and producers in the scientific 
community. Misconceptions that non-animal-derived 
antibodies may not fulfil the requirement of certain 
demanding applications, in comparison with the 
natural immune response, reliability in terms of 
cross-reactivity, stability, affinity, avidity specificity 
and functionality, and multi-epitope recognition are 
discussed below and briefly addressed in Table 1. 
More detailed examples of successfully developed 
antibodies from non-animal sources are presented in 
Section 8 and in the Appendix.
Certain scientific limitations that are common 
to both animal-derived and non-animal-derived 
affinity reagents exist due to the complexity of the 
natural antibody-antigen binding relationship. These 
difficulties arise due to conformational challenges 
presented by the antigen or the availability of the 
epitope. For example, complex biological samples, 
e.g., viruses or whole cells, present a challenge 
because it may be difficult to expose or access the 
desired epitope. In applications where the target 
has undergone considerable modification, e.g., 
denaturation during Western blotting (see Section 
5) or denaturation/chemical crosslinking during IHC, 
the epitope may no longer be displayed in its original 
form. Instead new epitopes become exposed. It should 
be noted that some degree of modification is likely in 
most applications. Therefore, different antibodies will 
be needed for different applications, independent of 
the method of generation.
Certain molecules, such as carbohydrates, have 
low immunogenicity due to the absence of the 
rich structural and chemical diversity typical of 
proteins and peptides. Animal-derived antibodies 
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Table 1: (Reprinted under CC BY-NC-ND 4.0 from Gray et al., 2016, Trends in Biotechnology, 34, p. 965-966, © 2016, Gray, Sidhu, Chandrasekera, Hendriksen and Borrebaeck 
published by Elsevier) Technical Comparison of Phage Display and Animal-Derived Antibodies.
© 2016, Gray, Sidhu, Chandrasekera, Hendriksen and Borrebaeck published by Elsevier
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suffer additional restrictions because of the T-cell-
independent antibody response to carbohydrates and 
failure to elicit memory responses. This can result in 
the production of low affinity and difficult to work 
with immunoglobulin M (IgM) antibodies to these 
molecules. (Heimburg-Molinaro and Rittenhouse-
Olson, 2009). New technological developments to 
solve this problem are discussed in Section 1.
A commonly expressed viewpoint is that in order to 
exploit the full potential of the immune repertoire, 
a whole animal immune response to an antigen is 
required. There is a large body of data showing that 
this is not the case (see Section 7). The underlying 
mechanistic, functional, structural and diversity-
generating similarities are discussed in Section 5 
to clarify how the non-animal-derived antibody 
development strategy has adopted and adapted the 
essential principles of the naturally evolving immune 
system during the generation of antibody candidates 
against a specific target.
A challenging issue for animal-derived antibody 
development is the generation of antibodies to self-
antigens or when there are high sequence homologies 
between the human and the respective animal-
derived antigen. Similarly, a commonly expressed, 
but erroneous, viewpoint is that recombinant libraries 
cannot deliver antibodies against antigens from the 
same species. While it is difficult to raise mouse 
monoclonal antibodies to mouse antigens, a synthetic 
library is not influenced by the tolerance mechanisms 
that wipe out B-cells producing self-antibodies 
during the immune response. Consequently, many 
human antibodies against human antigens have 
been successfully made from such libraries, many 
for clinical use, and a number of these have already 
been approved for therapy. Further, European Union 
funded academic consortia have demonstrated 
the generation of hundreds of human antibodies 
to human proteins, e.g., Affinomics, see Appendix, 
Section III. The misconception that recombinant 
antibodies have lower affinities than animal-
derived antibodies originated from the early years 
of recombinant antibody technology where most 
studies were executed with smaller libraries of lower 
functional diversity than routine today. There is clear 
evidence that antibody libraries with a larger number 
of functional antibody genes result in antibodies with 
higher intrinsic affinities (see Figure 3.5 in Hentrich 
et al., 2018). Early libraries were not sufficiently 
large to contain antibodies with affinities like mouse 
monoclonal antibodies.
This misconception of lower affinity was also amplified 
by confounding the intrinsic affinity measured from 
bacterially derived monovalent antibody fragments 
(typically scFv or Fab) with the apparent affinity 
(avidity) measured from bivalent IgGs. Consequently, 
monovalent antibody fragments generated from 
naïve libraries, or cloned from hybridoma cell lines, 
failed to achieve the same functional affinities as the 
natural bivalent antibody when directly compared in 
typical binding assays such as ELISA, western blot 
or SPR, even though the underlying true affinities (of 
the monovalent arm) may have been identical. Today 
recombinant antibodies can easily be produced in 
the bivalent IgG format or in many other bi- and 
multivalent formats (Plückthun and Pack, 1997; 
Frenzel et al. 2017), which can be produced in a 
variety of hosts.
In vitro selection systems used with recombinant 
libraries also present unique opportunities to optimise 
the panning conditions or affinity-mature to resolve 
any unforeseen binding issues as well as improve 
them beyond the typical values expected of traditional 
IgGs. As a rule of thumb, with modern naïve libraries, 
after selection, non-animal-derived antibodies can be 
expected to achieve binding affinities at least similar 
to those commonly observed in rat and mouse 
monoclonal antibodies (low nanomolar [nM] range). 
Sub-nanomolar affinities for antibodies obtained 
directly from sufficiently large naïve libraries have 
been frequently reported (Table 3.1. in Hentrich et al., 
2018). After affinity maturation, non-animal-derived 
antibodies can achieve affinities similar or better than 
those sometimes observed for rabbit monoclonal 
antibodies (sub-nM to low pM range).
For certain applications, polyclonal antibodies 
derived from serum and capturing the whole 
animal immune response are preferred, such as 
when multiple epitope recognition is required. It 
is assumed that non-animal-derived approaches 
cannot meet this requirement. However, in vitro 
selection strategies routinely identify multiple 
antibody candidates against the antigen’s various 
epitopes during the panning procedure. For example, 
Russo et al. (2018) isolated 11 highly specific scFv-
human Fc anti-zebrafish cadherin antibodies binding 
to at least 5 different epitopes of recombinant 
zebrafish cadherin. Recombinant approaches allow 
the choice between the selection of individual clones 
with the most appropriate binding characteristics 
to create a monoclonal reagent against a specific 
target, or to focus on a multiple epitope approach 
for applications such as complex or highly 
mutagenic targets (Haurum, 2006; Alvarenga et 
al., 2014). For applications where polyclonals have 
historically been relied upon, e.g., scorpion venom 
neutralisation, it should not be assumed that this 
approach is exclusive to the application, since it 
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is also possible to neutralise the closely related 
toxins by using a monoclonal approach (Riaño-
Umbarila et al., 2005). Polyclonals have been used 
historically for the generation of secondary reagents 
that recognise multiple binding sites within the Fc 
region of the primary antibody, for the purpose 
of fusion tag signal amplification. Recently it was 
demonstrated, however, that recombinant antibody 
fragments (VHH fragments in this case) made 
against all mouse IgG subclasses and rabbit IgG 
can outperform polyclonal secondary reagents 
(Pleiner et al., 2018). To assist with the availability 
of one such VHH secondary reagent, the sequences 
and methods have been made accessible to the 
public and the expression plasmids are available 
on Addgene (Ewers, 2018). Those VHH reagents 
were developed by immunisations of llama and 
are therefore animal-derived. However, they prove 
that monoclonal secondary reagents with superior 
quality over polyclonals can be generated.
A non-animal derived alternative to polyclonal 
antibodies for signal detection and amplification 
are “multiclonal” antibodies recognising the IgG Fc 
region (https://abcalis.com/multiclonals/). Here, up to 
seventeen recombinant sequence defined monoclonal 
antibodies derived by phage display from universal 
libraries are combined to provide multiple epitope 
recognition, thus allowing to replace current animal 
derived secondary antibodies.
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Figure 5: (Reprinted under CC BY-ND from Bradbury et al., 2011, Nature Biotechnology, 29, p. 246 © 2011, Springer Nature) 
The unique capabilities of in vitro selection offer advantages over the immunisation of animals for antibody generation. The 
direct coupling of the antibody and its encoding gene is characteristic of all display methodologies, including phage, yeast and 
ribosome display.
7. New opportunities made available using non-animal-derived antibodies
Since the natural immune response is mimicked and 
adapted during recombinant library selections, the 
previous limitations observed with animal-derived 
antibodies are avoided and replaced by a much more 
controlled generation of binding reagents.
7.1 Non-animal-derived antibodies are 
invariably sequence defined as part of 
their isolation
The sequences of non-animal-derived antibodies are 
typically determined as part of their isolation process, 
whereas this feature, i.e., known sequence, cannot be 
acquired for polyclonals, and only with significant 
additional effort for animal-originating hybridoma-
derived monoclonal antibodies. Consequently, the 
sequences of antibodies contained in a polyclonal 
serum sample are never known and will change 
when preparing subsequent batches. The sequences 
of hybridoma-derived antibodies are rarely known.
Sequencing is an integral part of recombinant 
antibody generation during the initial identification 
of a clone. In consequence, once the sequence 
has been documented, the cell clone could be 
lost, but the corresponding antibody can be easily 
reconstituted by gene synthesis to obtain the 
identical specificity and binding profile. This factor 
allows unlimited reproducibility of scientific data, 
very much in contrast to classical polyclonal 
research data which can never been repeated 
exactly once the limited amount of animal blood 
serum is depleted. Monoclonal antibody producing 
hybridoma cell lines require (expensive) ultra-deep 
freezing for long-term storage and a large number 
of monoclonal antibodies described in the literature 
are thought to have been lost already, also limiting 
the reproducibility of the respective experiments 
(Bradbury and Plückthun, 2015a). The logistics of 
creating redundant storage of cell lines should be 
compared with the trivial logistics of redundantly 
storing a computer file of the sequence.
Since during in vitro antibody selection, the gene 
encoding the antibody is cloned at the same time as 
the antibody is selected, simple subcloning steps after 
in vitro selection permit the creation of constructs 
with added functionalities, as depicted in Figure 5.
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7.2 Unique features of antibodies enabled 
by display technologies
By permitting control over selection and screening 
conditions, display technologies allow the generation 
of antibodies against defined antigen conformations 
or epitopes. For instance, the inclusion of competitors 
can direct selection toward specific targets. Antibody 
specificities can be broadened or narrowed by 
appropriate selection and screening (Figure 6).
7.3 More flexibility in the use of antibodies
In contrast to animal-derived antibodies, the 
researcher using recombinant antibodies is not 
limited by the choice of a particular detection 
system. All in vitro selection systems immediately 
provide the genes and corresponding sequences 
of antibodies selected against a particular target. 
This provides ready access to additional antibody 
formats by simple subcloning and expression. 
Functions adopted using this “gene-based” approach 
includes dimerisation, multimerisation and fusions 
to enzymes, tags or fluorescent proteins. Fusion 
to bacterial alkaline phosphatase is a particularly 
useful example of improved functionality (Weiss 
and Orfanoudakis, 1994). Antibody fragments can 
also be transformed into full-length antibodies, 
or scFv-Fc fusions, which are very similar in many 
aspects (Bradbury et al., 2011). The genetic fusion 
of antibody genes to DNA encoding Fc parts from 
different species permits selection of the conventional 
secondary detection system in many immunoassays. 
For example, antibodies selected from the same 
universal human antibody phage display can carry 
either a mouse, rat, human, rabbit or other Fc part 
(Figure 7). Alternatively, or additionally, it can carry 
any variety of tags, including those for site-directed 
biotinylation. Recent developments in protein ligation 
technologies such as the Sortase system (Schmohl 
and Schwarzer, 2014) or the SpyTag system 
(Reddington and Howarth, 2015) circumvent the re-
cloning step by enabling site-specific attachment of 
Fc parts or other moieties directly to the antibody 
fragment obtained from library selections.
Figure 6: (Reprinted with permission from Frenzel et al., 2017, Tranfusion Medicine and Hemotherapy, 44, p. 313, © 2017, 
Karger Publishers, Basel, Switzerland). Antibody phage display. In an antibody phage particle, the antibody gene and the function 
it encodes (antigen binding) are physically linked. This allows the affinity selection of monoclonal human antibodies in the test 
tube (a process named "panning”), e.g. panning in the presence of soluble competitor to deplete cross-reacting antibodies, 
panning under defined biochemical conditions selects only antibodies that are functional at these conditions, or sequential 
panning rounds on two different but homologous antigens allow to functionally select antibodies that bind to a structural feature 
common to the two proteins.
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For example, this allows visualising three different 
biomolecules in a cell by using three different colours, 
which are recognised by three different antibodies 
carrying Fc parts from three different species (Figure 
8). The possibility to engineer Fc regions to carry 
mutations that suppress Fc-receptor binding (LALA, 
TM, or N297A mutations) and therefore reduce 
background in flow cytometry experiments has 
been mentioned above (see Section 7.1). Respective 
antibody variants using the same recombinant 
binding site with different Fc parts for detection are 
already commercially available.
Even more colours could be added, e.g., by using 
biotinylation tags and streptavidin, plus other tags 
in addition, including direct GFP fusions. This cannot 
be achieved with typical state-of-the-art animal-
derived antibodies.
Figure 7: (© 2020, Dϋbel under CC BY 4.0) Animal-free generation of antibodies functioning as if generated from different 
animals: The scFv-Fc antibody format has been shown to be functionally equivalent to full IgG in a large number of applications, 
including the most widely used ones (immunoblot, immunohistochemistry/ immunofluorescence, FACS ) (as shown by hundreds 
of examples within the EU funded Program Affinomics, see Appendix, Section III). It allows a simple combination of the antigen 
binding site (defining the antibody specificity) with different Fc parts for detection.
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7.4 Improving antibody affinity and 
specificity
After initial generation, non-animal-derived 
antibodies can be improved in many aspects by in 
vitro evolution of the encoding DNA. “Libraries of 
mutagenized variants can be created and the same 
selection process repeated to yield variants with 
superior specificity and affinity. The improvement 
of antibody affinity to picomolar levels has become 
relatively routine, with one study describing an 
antibody that reached femtomolar affinity after in 
vitro maturation. These affinities are far higher than 
those of antibodies obtained by immunisation, which 
are usually limited to ~100 pM by the physiological 
mechanism of B-cell activation.” (from Bradbury et al., 
2011). Even parameters of the binding kinetics can 
be optimised by directed evolution and appropriate 
selection parameters to fit the experimenter’s need, 
like the association and dissociation rates shown 
in the following example (Figure 9). The physical 
constraints and experimental set-ups needed are 
well understood (Zahnd et al., 2010).
Figure 8: (Reprinted under CC By 2.0 from Moutel et al., 2009, BMC Biotechnology, 9, p. 5, © 2009, Springer Nature) 
Immunofluorescence using multi-species variants of recombinant antibodies. A: The scFv-Fc F2C (a-c), SF9 (d-f), TA10 (g-i) and 
AA2 (j-l) in their human (a, d, g, j), mouse (b, e, h, k) or rabbit (c, f, i, l) versions can be used in immunofluorescence to detect 
their respective target proteins with similar efficiency (red). Bar = 20 μm. B: Using the multi-species approach, antibodies can be 
produced fused to any of the three IgG species. This allows a large diversity of multiplexing. In this example, myosin, tubulin and 
giantin were co-detected in HeLa cells using the human version of SF9 (a), the mouse version of F2C (b) and the rabbit version 
of TA10 (c) respectively. The three labellings are shown overlaid in (d). Bar = 20 μm.
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KD = 7x10 -10 M  
koff = 1.49x10-3 s -1
on -rate optimised KD = 8x10-10 M  
koff = 1.18x10-4 s -1
off -rate optimised:
Figure 9: (Reprinted with permission from Frenzel et al., 2017, Tranfusion Medicine and Hemotherapy, 44, p. 316, © 2017, 
Karger Publishers, Basel, Switzerland) An example for selective variation of association and dissociation rate constants observed 
upon light chain shuffling and selection using phage display with different selection parameters. The heavy chain of an antibody 
candidate was re-shuffled with the entire light chain repertoire of the naïve human library. After screening with different 
conditions, antibodies with different binding kinetics were obtained while maintaining the original high affinity, as determined 
by surface plasmon resonance.
7.5 Additional applications enabled by 
the recombinant nature of antibodies 
selected in vitro
Since the sequence is known and the DNA encoding 
the antibody is available from the start, the antibody 
fragments from animal-free generation methods 
can also be used right away in applications typically 
not possible for animal-derived antibodies, e.g., the 
use as intrabodies by expression in cells bearing 
the antigen, thus generating a protein knock down 
phenotype (for extensive review see Marschall et al., 
2015) the expression on cells, e.g., to create CAR-T 
cells (June et al., 2018) or to redirect viruses to infect 
particular cell types (Buchholz et al., 2015).
.
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8. Non-antibody affinity reagents or “scaffolds”
Ever since affinity reagents could be generated from 
a fully synthetic gene library, research had focused 
on substitution of the IgG protein framework by 
other protein scaffolds that could provide certain 
advantages in particular applications, whilst retaining 
the highly advantageous principles of diversity, 
selection and evolution that are characteristic of 
all affinity reagents (see Section 5). In other words, 
as an alternative to replacing animal-derived IgGs 
with recombinant IgGs (or Fab and scFv fragments), 
other protein scaffolds were designed to exploit 
the additional opportunities provided by protein 
engineering with greater ease. Thus, the main 
justification of using non-antibody scaffolds over 
recombinant antibodies is to extend the application 
range of binding reagents (for review, see Škrlec et 
al., 2015), as well as exploiting their generally more 
robust nature, being advantageous for all applications. 
A particular advantage of several scaffolds is their 
highly efficient and inexpensive production in E. coli, 
providing cost-effective access to applications where 
larger quantities are needed, e.g., affinity purification 
of targets, or structural biology. Due to the extremely 
straightforward bacterial expression and purification, 
even inexperienced laboratories can express and 
purify these affinity proteins themselves, permitting 
the shipment of plasmids instead of proteins, or even 
only electronically transmit just the DNA sequence.
Several scaffolds are free of cysteines and fold 
well in the cytoplasm of cells, facilitating their 
application as intrabodies that work in the reducing 
environment of the cytoplasm. Domains devoid 
of beta-sheets are generally more robust against 
aggregation. Fusion proteins of such scaffolds 
with GFP, viral surface proteins or transmembrane 
anchors usually fold reproducibly well and are thus 
well expressed in any host. This is not always the 
case with beta-sandwich domains such as those 
from antibodies. For the same reason, robust scaffold 
proteins can also be homo- and hetero-dimerised 
and -oligomerised in many formats and geometries. 
These are well expressed in bacteria, where they 
generally fold well, while this is often only possible 
in eukaryotic hosts for antibody domains.
The best proof of appropriate specificity and affinity 
of such scaffold proteins is the fact that several 
of them have been used in drug discovery and are 
now in late-stage clinical trials (Simeon and Chen, 
2018), which require specificity and good biophysical 
properties. The scaffolds that have reached clinical 
stage are also non-immunogenic. The flip side is that, 
at the time of writing, the companies developing 
these scaffolds do this for therapeutic applications 
only, entirely for economic considerations. However, 
the reagents are available to researchers through 
collaborations with several academic laboratories 
and facilities that have generated them for non-
commercial purposes, some in high throughput 
(Appendix, Section V.b). Since numerous publications 
have greatly increased awareness and demand, 
it is only a matter of time until they will become 
commercially abundant.
In principle, every protein can be converted into a 
library of highly diverse binding proteins, but to 
achieve the desired properties for enabling the 
applications listed above, a particularly stable 
scaffold having a suitably large interaction surface 
and a well-conceived randomisation strategy needs 
to be used. A large number of non-antibody scaffolds 
have been explored (Binz et al., 2005; Caravella and 
Lugovskoy, 2010; Gebauer and Skerra, 2009; Gilbreth 
and Koide, 2012; Simeon and Chen, 2018; Weidle et 
al., 2013; Jost and Plückthun, 2014) and we direct the 
reader to the above excellent reviews summarising 
many of these aspects.
By way of example, Designed Ankyrin Repeat 
Proteins (DARPins) may serve to illustrate a mature 
technology (Plückthun, 2015). Different libraries 
have been made (see Binz et al., 2004; Schilling 
et al., 2014) and selections have been carried out 
with ribosome display (Dreier and Plückthun, 2012), 
phage display (Steiner et al., 2008) and yeast display 
(Schütz et al., 2016). Binders against several hundred 
targets have been created, largely within academic 
collaborations for research purposes using high-
throughput ribosome display in selections with 
92 targets in parallel. Several DARPins are in late-
phase clinical trials (NCT03418532, NCT03136653, 
NCT02194426, NCT03084926, NCT03539549, 
NCT02462486, NCT02186119, NCT02462928, 
NCT02181517, NCT02181504) with constructs 
containing one through five different fused DARPins. 
Clinical applications of these DARPins was possible 
because of their lack of immunogenicity.
The published use of reagent DARPins have ranged 
from immunohistochemistry (Theurillat et al., 2010), 
large scale affinity purification (Hansen et al., 2017), 
SPR immobilisation (Hansen et al., 2017), virus 
retargeting (Bender et al., 2016; Friedel et al., 2015; 
Friedrich et al., 2013; Hanauer et al., 2016; Hartmann 
et al., 2018; Münch et al., 2011; Münch et al., 2015; 
Schmid et al., 2018), intracellular sensors (Kummer 
et al., 2013; Kummer et al., 2012), crystallisation 
chaperones (Batyuk et al., 2016; Wu et al., 2017; 
Wu et al., 2018), or research on cancer mechanisms 
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(Schwill et al., 2019; Tamaskovic et al., 2016; 
Tamaskovic et al., 2012), to name a few examples.
Other scaffolds may have advantages for particular 
applications, e.g., anticalins (derived from lipocalins) 
have a rather deep pocket and may be advantageous 
in binding smaller biomolecules (Rothe and Skerra, 
2018); while armadillo repeat proteins bind extended 
protein chains and may not only be useful for the 
detection of linear epitopes but also be developed 
into a modular sequence recognition technology 
(Hansen et al., 2018; Hansen et al., 2016; Reichen et 
al., 2014) that would eventually avoid the selection 
against every individual target altogether, with great 
cost-saving potential.
Currently, one obstacle to a wider adoption of non-
antibody scaffolds is the present lack of commercial 
availability, which is due to the companies’ business 
models. This may change rapidly, as some of the 
key patents will expire soon, but today respective 
catalogue research reagents are still rare. Thus, most 
academic research has come from collaborations 
with the generators of the various scaffolds. 
However, the scaffolds certainly offer promising 
features which may boost their application to replace 
animal-derived antibodies in the future. While their 
generation and quality-control cost is very similar 
to non-animal-derived antibodies, the subsequent 
protein production, i.e., the expression and purification 
from an existing gene) could be significantly cheaper, 
for example when based on high-yielding bacterial 
expression. This can drive the price below that of 
monoclonals today, and with further technology 
development, as well as the prospect of a modular 
sequence recognition technology (Hansen et al., 
2018; Hansen et al., 2016; Reichen et al., 2014), 
perhaps even below those of polyclonals.
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9. Future directions
The generation of non-animal-derived antibodies 
and other affinity ligands offers a superior scientific 
resource compared to animal-derived polyclonal 
and monoclonal antibodies. Their selection can be 
controlled in vitro, they can be generated against “self-” 
molecules and against toxins, their sequences are 
known, they can be engineered and their recombinant 
nature provides a consistent reproducible resource. 
Commercial producers, government authorities, 
funding agencies and academics, worldwide, have the 
opportunity to place far greater emphasis on antibody 
generation and validation by using non-animal-derived 
antibodies and scale down production of antibodies 
by methods that rely on animal immunisation. Here 
also lies the opportunity to improve awareness, 
cost, training and education, accessibility, which will 
automatically drive up demand for all non-animal-
derived affinity reagents.
There is limited awareness of the fact that several 
thousands of animal-derived antibodies exist against 
the same popular targets. It has been calculated that 
there are 3483 protein targets with 100 or more 
antibodies and 42 proteins with over 1000 antibodies 
to each of the targets. The record is held by epidermal 
growth factor receptor (EGFR) with 8537 antibodies 
from 58 providers (https://www.antibodypedia.com). 
Duplication of many of the more popular targets 
reflects that the commercial market is driven to those 
targets of high demand — obviously a self-fulfilling 
prophecy, as researchers will work on targets with 
available reagents. A “reset” with new batches of 
recombinant reagents may have the potential of 
“evening out” the research on different and new 
therapeutic targets, provided appropriate subsidies 
are in place to reward such broader approaches. The 
relation between supply and demand is bidirectional.
Creating awareness and educating the typical user of 
research antibodies about the above misconceptions 
and current status is best achieved by two 
components: by making such non-animal-derived 
reagents conveniently available (see below); and 
by generating an increased number of successful 
case studies, ideally matched to convince today’s 
patchwork of quite diverse research communities. 
Unfortunately, as of today, the reagents for this 
endeavour are simply not yet available off-the shelf. 
While they can all be custom-made, commercial 
efforts in generating such molecules have focused 
almost exclusively on therapeutic products and 
so the industrial capacity for producing research 
reagents is still low. Such custom-made non-animal-
derived products will have to compete for some time 
with animal-derived catalog antibodies. Since the 
price cannot currently be undercut, the recombinant 
product must be positioned for its higher quality and 
greater opportunities (see Section 7 and Section 8).
There is also still ample potential to make 
recombinant research antibodies generated by 
phage display even cheaper, and probably even 
more so for other non-antibody scaffolds based 
on other selection technologies. One effective 
direction currently being followed is the creation 
of specialised binding domains, derived from low-
affinity enzymes or binding domains, improved 
through directed evolution, to exploit already existing 
binding specificities, e.g., to detect ubiquitin-modified 
proteins (Tandem Ubiquitin Binding Entities (TUBEs), 
lifesensors.com), ADP-ribosylated proteins (Leutert et 
al., 2018), or glycosylated proteins (Hu et al., 2015). 
It is not necessary to have the same scaffold or the 
same universal library for all target molecules — for 
the end user, the assay will work identically.
The EU has already made some significant progress 
to support the development of recombinant affinity 
reagents: it has invested significant funding for 
several consortia which included tasks to parallelise 
and miniaturise in vitro antibody and binder 
generation. The goal to reach cost levels comparable 
to animal-derived monoclonal antibodies has already 
been achieved by these consortia (Appendix, Section 
III). Yet, with high probability of success, further large 
reductions could be achieved by further parallelisation 
and miniaturisation and by applying this technology 
to larger numbers so that a significantly lower cost of 
goods can be envisaged here.
The reason why such further improvements have 
not been pursued already by companies is a vicious 
circle: Profit margins and sales volumes per product 
in the research reagent markets are small and cannot 
fund substantial technological developments. In the 
development of therapeutics, the contribution of binder 
generation to the overall cost of clinically developing 
a therapeutic is almost a rounding error, such that 
there is no incentive for such technology development, 
either. As long as the misconceptions among potential 
customers exist that “phage display” antibodies are 
unreliable and expensive, such investments are still 
unattractive for companies, leading in turn to fewer 
examples of success stories. Indeed, some scientists 
are of the impression that recombinant antibodies 
must have bad properties, only based on the fact that 
there are so few in the catalogues.
Demand is also curbed by the limited availability: 
the current commercial cost of custom-made 
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antibody generation by recombinant methods is 
somewhat higher than the generation of traditional 
monoclonals, meaning that customers, guided 
by budget constraints, are choosing to accept 
a sub-standard research tool (see Section 6.3). 
As mentioned, commercial efforts in generating 
such molecules have gone almost exclusively into 
therapeutic products. Although costs will decrease 
as antibody generation by in vitro methods becomes 
more common-place, an impetus is needed during 
the transitional phase. To ensure scientific and 
ethical standards are met, the EU Governments 
could allocate subsidies to antibody producers or 
customers requiring custom antibody production, 
who satisfy eligibility criteria. Alternatively or 
additionally, non-profit centres (akin to the academic 
animal facilities of today and the academic DNA 
synthesis and peptide synthesis facilities of the past) 
may provide such recombinant binder generation 
services to the community for a transition period, 
until the commercial sector takes over. To ensure 
researchers are incentivised, regulatory standards 
should also reflect the high quality scientific and 
ethical core values.
Since there is a wide-spread acceptance of the 
limitations of antibodies, which are considered 
“intrinsic”, fuelling the continued production of 
animal-derived antibodies and limiting the potential 
for non-animal-derived antibodies to gain a greater 
foothold in the market, the demand for a scientifically 
superior resource has to be created. This can only 
come from government authorities, funding agencies 
and publishers, supporting higher quality scientific, 
regulatory and ethical standards. For example, one 
proposal is that all newly generated binding reagents 
proposed in funding applications or described in 
published papers should be non-animal-derived, 
from naïve universal recombinant libraries or other 
non-animal-derived suitably engineered sources and 
defined at the sequence level. This would parallel 
the instilled standard that has existed for the past 
few decades, namely that gene sequences and 
coordinates for new protein structures be deposited 
and made publicly available. Making sequenced 
well-characterised reagents and ensuring all binding 
reagents in published papers are recombinant 
and defined at the sequence level, in conjunction 
with stringent quality control of the reagents, has 
previously been called for (Bradbury and Plückthun, 
2015a) and is reiterated here.
Where the requirement for high scientific quality, 
reliability and consistency over long periods of 
time is of paramount importance, i.e., where it is 
anticipated that antibodies may be destined for 
use in diagnostics, batch testing of biologicals or 
otherwise regulated test methods, or as a tool for 
analysis, the use of animal-derived monoclonal or 
polyclonal antibodies can be avoided. In this case, the 
use of in vitro universal libraries enables sequencing 
data from candidate clones to be routinely collected 
and logged, avoiding that clones may succumb to 
any of the problems described in Section 4. Similarly, 
the results of biomedical research can influence the 
development of diagnostic tests and therapeutic 
development. Therefore, researchers carry an 
enormous responsibility to contribute to reproducible 
standards that follows the same requirements.
If these commitments are made, scientists will not 
want to use animal-derived antibodies and demand 
will follow. The absence of the adopted standards will 
lead to market disadvantages, which will encourage 
competitors beyond European legislative control to 
raise their standards.
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11. List of Abbreviations
CAR-T cells Chimeric antigen receptor T cells
ChIP  Chromatin immunoprecipitation
DARPins Designed Ankyrin Repeat Proteins
DNA  Deoxyribonucleic acid
dsFv   Disulfide-bond stabilised Fv
E. coli  Escherichia coli
ELISA  Enzyme-linked immunosorbent assay
ESAC  EURL ECVAM Scientific Advisory Committee
EU  European Union
EURL ECVAM European Union Reference Laboratory for alternatives to animal testing
Fab  Fragment antigen-binding
Fab-A  Fab fused with alkaline phosphatase
FACS  Fluorescence-activated cell sorting
Fc  Fragment constant
FFPE tissue Formalin-fixed paraffin-embedded tissue
FRET  Fluorescence resonance energy transfer
Fv  Fragment variable
GFP  Green fluorescent protein
HER2  Human epidermal growth factor receptor 2
Ig  Immunoglobulin
IgG  Immunoglobulin G
IHC  Immunohistochemistry
MFI  Mean fluorescence intensity
MRM  Multiple reaction monitoring
nM  Nanomolar
PCR  Polymerase chain reaction
pM  Picomolar
scFv  Single-chain fragment variable
scFv-Fc  Single-chain fragment variable dimerised by the fragment constant (Fc) domain
SPR  Surface plasmon resonance
VH  Variable heavy
VHH  Single variable heavy domain (heavy chain only antibody from camelids)
vNAR  Variable new antigen receptor
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12. Appendix
Case studies
I Non-animal-derived antibodies in clinical use
The following link summarises phage display-derived antibodies that are approved for therapy or in clinical 
development. The vast majority being non-animal-derived (synthetic, semi synthetic or non-immunised/
naïve): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058633/table/t0001/?report=objectonly. A selection of 
these antibodies is described in more detail in the corresponding review (Frenzel et al., 2016), demonstrating 
different aspects of the phage display technology and its development over the last 25 years. For further 
information, also see https://www.antibodysociety.org/ and Nelson et al., 2010.
II Use of antibodies in regulatory procedures: The human Cell Line Activation Test (h-CLAT; 
OECD TG442E)
Skin sensitisation is the regulatory endpoint aiming at the identification of chemicals able to elicit an allergic 
response in susceptible individuals. Following repeated exposure to a sensitising agent, the adverse health 
effect of allergic contact dermatitis (ACD) may be provoked. Thus, the development of ACD is characterised 
by two distinct phases: the induction of specialised immunological memory following the initial exposure to 
an allergen, called sensitisation, and elicitation of the clinical allergic response following subsequent exposure 
to the allergen. Regulatory adopted animal-based tests, which are part of Council Regulation No 440/2008 
(EU, 2008), include: Local lymph node assay, LLNA (OECD TG 429; OECD, 2010a), and its non-radioactive 
modifications, LLNA-DA (OECD TG 442A; OECD, 2010b) and LLNA-BrdU Elisa (OECD TG 442B; OECD, 2018a); 
Guinea pig maximisation test, GPMT, by Magnusson and Kligman (OECD TG 406; OECD, 1992); and Buehler 
occluded patch test in the guinea pig (OECD TG 406; OECD, 1992).
The human Cell Line Activation Test (h-CLAT) is cited as an alternative to animal-based test methods for the 
measure of skin sensitisation. The h-CLAT measures the expression of the CD86 and CD54 membrane markers 
in THP-1 cells, a human monocytic leukaemia cell line used as a surrogate model for dendritic cells. The 
expression levels of the markers are measured by flow cytometry following 24 hours of exposure to eight serial 
concentrations of test chemical selected on the basis of a pre-determined CV75, i.e. the concentration of test 
chemical that allows 75% of cell survival). The test method is designed to discriminate between sensitising and 
non-sensitising chemicals whereby chemicals are classified as sensitisers if the relative fluorescence intensity 
(RFI) of either CD86 and/or CD54 exceeds a defined threshold, i.e. RFI CD86≥150 and RFI CD54≥200, compared 
to the vehicle control wells at any tested concentration, in at least two out of three independent measurements. 
The h-CLAT is expected to be used in conjunction with other methods to be able to replace the current animal 
tests. Such complimentary information may come from other testing methods that address other key events 
involved in skin sensitisation. Examples of such alternative methods might include the Direct Peptide Reactivity 
Assay (DPRA-OECD TG 442C; OECD, 2015) and/or the Keratinosens assay (OECD TG 442D; OECD, 2018b).
However, whilst classed as an animal replacement method, the h-CLAT has been developed using several 
animal components including foetal calf serum and animal-derived antibodies. xCellR8 is a UK-based, GLP-
accredited laboratory, specialising in animal-free safety and efficacy tests for the cosmetics, personal care 
and chemical industries. In response to direct requests from companies in the cosmetics and personal care 
sectors, XCellR8 adapted the h-CLAT method by replacing the animal components 10% FBS/FCS and the 
mouse anti human CD54 and CD86 monoclonal antibodies with 10% Human Serum and custom nonanimal-
derived anti-CD54 and anti-CD86 antibodies produced by Bio-Rad using the HuCAL® technology (Human 
Combinatorial Antibody Library). To assess the performance of the HuCAL antibodies, quality control ELISA 
and dissociation rate assessment (koff ranking) were used as selection criteria.
xCellR8 sought to obtain regulatory acceptance of the adapted method by submitting a proposal to the OECD 
Working Group of the National Co-ordinators of the Test Guidelines Programme (WNT) detailing the inclusion 
of an adapted h-CLAT method into OECD TG 442E (OECD, 2018c) which would allow global use of a novel 
animal-free integrated approach to testing and assessment for skin sensitisation. The project proposal was 
accepted by the WNT at its annual meeting in April 2018.
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XCellR8 demonstrated the satisfactory performance of the adapted h-CLAT method in passing the acceptance 
criteria as specified in OECD TG 442E (OECD, 2018c), where: 9/10 CV75 values were within range; 10/10 
substances were correctly classified as sensitisers or non-sensitisers, and 8/10 substances met the EC150 
and EC200 ranges specified and now awaits a decision regarding the regulatory acceptance of the adapted 
h-CLAT test method.
xCellR8s OECD proposal aims to replace animal products with human reagents to achieve xeno-free culture 
conditions and to provide the cosmetics industry, including its supply chain, with truly animal-product-free 
versions of the in vitro test methods for skin sensitisation, while maximising the scientific relevance of the 
methods for human safety. Further to this line of reasoning, is the significance of replacing the animal-derived 
antibodies with higher scientific quality, sequence defined antibodies, as described throughout this report, to 
make available a more scientifically reliable regulatory test method and instil a standard, which should be 
adopted in the future development of validated alternative test methods. Although in this case, the test method 
is subject to proficiency testing, the specificity of the original antibodies is undetermined and the sequence of 
the antibodies is undefined. If the hybridoma is lost in the future, the test method will be compromised. Whilst 
the adapted h-CLAT test method serves as a good example of the replacement of animal-derived antibodies 
by phage display antibodies in a regulatory test method, it is hoped that the extensive assessment, review and 
acceptance process can be avoided in the future by adding the incorporation non-animal-derived antibody as 
a pre-requisite in future test method developments.
III European Union (EU) / US National Institute of Health (NIH) projects demonstrating the 
feasibility of generating large numbers of antibodies
A major objective of the post-genome era is to detect, quantify and characterise all relevant human proteins 
in tissues and fluids in health and disease. Substantial funding has been committed to pan-European and US 
based initiatives to generate sets of well characterised and harmonised renewable binding reagents (including 
non-animal-derived antibodies and scaffolds) for the human proteome. Renewable binding reagents in this 
context refer to reagents that are recombinantly produced from a known sequence. The majority of these 
clones are not yet used today due to a lack of follow up studies for individual characterisation.
III.a  The Renewable Protein Binder Working Group
A forerunner of AFFINOMICS, this proof of concept exercise, part-organised by The Structural Genomics 
consortium, https://www.thesgc.org/, was set up to raise binders in a coordinated fashion against 20 individual 
Src Homology 2 (SH2) domains. Eleven international collaborating groups showed that it was possible to move 
quickly to a productive outcome. Over 500 renewable binders of different types were made (165 monoclonal 
antibodies, 340 unique recombinant single-chain fragments variable (scFV), which were confirmed to work 
in ELISA, Western blot, immunohistochemistry (IHC) and on microarrays of folded SH2 domains or protein 
fragments (PrESTs). The binders were produced in an impressively short space of time (3 months), 25% 
had better than 10 nM affinities and some could discriminate very closely related targets. This project was 
important in demonstrating that a binder-raising project, although on a relatively small scale in regard to 
target number, could be carried out efficiently (Colwill et al., 2011; Mersmann et al., 2010).
III.b  Proteome binders - A European Infrastructure of Ligand Binding Molecules Against the Human 
Proteome (1 March 2006 - 31 May 2010): https://cordis.europa.eu/project/rcn/78471/factsheet/en
Co-oordinated by Babraham Bioscience Technologies, this project integrated existing infrastructures, reviewed 
technologies and high throughput production methods, standardised binder-based tools and applications, 
assembled bioinformatics and established a database schema for a central binders repository. The project 
comprised the planning phase for the coordinated systematic development, production, resource management 
and quality control of a European resource infrastructure of characterised and standardised ligand-binding 
reagents under the 7th Framework Programme of the European Commission. These included antibodies 
(animal-derived and non-animal-derived antibodies), novel protein scaffolds and nucleic acid aptamers, 
directed against the entire human proteome (Taussig et al., 2007).
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III.c  Affinity Proteome - Advanced affinity tools and technologies for high throughput studies of the 
human proteome (1 March 2009 - 29 February 2012): https://cordis.europa.eu/project/rcn/90292/
reporting/en
Following on from the planning phase, this project focused on production of recombinant binders (antibody 
fragments, Designed Ankyrin Repeat Proteins [DARPins], aptamers) and advanced detection methodologies 
(microarrays, proximity ligation, intrabodies) for analysis of proteins in two critical signal transduction 
pathways, namely the mitogen-activated protein (MAP) kinase and transforming growth factor beta (TGF-
beta) pathways. Specifically, the objectives were to define and produce targets, by recombinant expression 
in bacteria or peptide synthesis. Then, to select the binders and establish methods for their characterisation 
and adaptation to application systems. Since the pathways investigated are frequently disturbed in major 
diseases, the availability of the binders generated in the project intended to be of benefit in medical research 
and development of new diagnostic assays. The project addressed issues of throughput, sensitivity, cost, 
validation and quality control, to develop technical solutions to a level where they could be exploited as 
commercial products. Some of the non-animal-derived antibodies made in this consortium are commercially 
available from Abcalis (https://abcalis.com/), with plans to add more in the future.
III.d  Affinomics - Protein Binders for Characterisation of Human Proteome Function: Generation, 
Validation, Application (1 April 2010 - 31 March 2015): https://cordis.europa.eu/project/rcn/94419/
reporting/en
Affinomics initiated the generation of a proteome-wide binder collection and to this end the consortium 
integrates the expertise and technologies available in 19 leading European centres and one small and medium-
sized enterprise (SME) in order to create an efficient pipeline for target and binder production validation 
and quality control. The pipeline included traditional polyclonal and monoclonal antibodies, but was strongly 
geared toward phage display and ribosome display for recombinant binder formats to increase throughput 
and reduce cost. The biomedical focus was on the characterisation of 5 classes of proteins involved in signal 
transduction pathways in normal and cancer cells and consisted of 1429 target proteins, 2900 antigens and 
5595 binders to kinases, phosphatases, SH2 domains, proteins mutated in cancer and plasma biomarkers. 
Some of the non-animal-derived antibodies made in this consortium are commercially available from Abcalis 
(https://abcalis.com/), with plans to add more in the future.
III.e  The US NIH Common Fund Protein Capture Reagents programme RM-10-017 / RFA RM-10: 
https://commonfund.nih.gov/proteincapture
The goal of the US Common Fund’s Protein Capture Reagents program is to develop a community resource 
of renewable, high-quality protein capture reagents, with a focus on the creation of transcription factor 
reagents and testing next generation capture technologies. The ultimate aim is to understand the critical role 
the multitude of cellular proteins play in development, health and disease. These resources will support a 
wide-range of research and clinical applications by enabling the isolation and tracking of proteins of interest. 
Its database at https://proteincapture.org lists 350 entries for highly validated recombinant antibodies. These 
are produced by the Recombinant Antibody Network (RAN), which is a consortium of three expert centres at 
the University of Chicago, University of California San Francisco (UCSF) and the University of Toronto (http://
recombinant-antibodies.org). A further 1172 animal-derived monoclonal antibodies are contributed by The 
Johns Hopkins University (JHU) and CDI Laboratories, Inc. (CDI). Therefore, the focus on recombinant antibody 
production is relatively small (Blackshaw et al., 2016).
III.f  The Antibody Factory (2004-2006)
Based at The Technical University of Braunschweig, Germany, this Federal Ministry of Education and 
Research (BMBF) funded pilot initiative produced and commercialised user-friendly, cost-efficient “design 
antibodies” using phage display from non-animal-derived sources to produce 461 recombinant monoclonals 
(scFv) from naïve libraries to 204 antigens. The final report is available in German: https://edocs.tib.eu/files/
e01fb08/585656304l.pdf.
ANNEx 2 - ESAC WORKING GROUP REPORT  |  61
III.g  ATLAS of protein expression group at the Sanger Institute (2002-2007)
Funded by the Wellcome Trust, this group constructed a high quality phage display library containing over 1010 
human antibodies and used it to generate, select, screen and sequence over 38,000 recombinant antibodies 
to 292 antigens, yielding over 7,200 unique clones. As many as 4,400 antibodies were characterised by 
specificity testing and detailed sequence analysis and the data/clones were made available online and to buy 
from Geneservice in Cambridge, UK, now Source Bioscience (Schofield et al., 2007). Full details of the ATLAS 
scFV Library, (Source Species: mouse or human; vector: pSANG14-3F; host Species: Escherichia coli; Host 
Strain: TG1) including a database listing 2400 clones from 135 unique targets, can be found at https://www.
sourcebioscience.com/products/life-sciences-research/clones/artificial-antibody-libraries/atlas-scfv-library/.
Project Lab Binder format no. binders Targets
Affinomics Braunschweig scFv-Fc 898 191
Affinomics Lund scFv 1068 206
Affinomics Zürich DARPin 185 185
Affinity Proteome Braunschweig scFv 122 40
Affinity Proteome Zürich DARPin 8 8
Sanger Sanger scFv 7236 292
Antibody Factory Braunschweig scFv 461 204
SGC-Pilot SH2 scFv/Fab 340 20
TOTAL 10318 1146
IV Data supporting Section 5.5 of the main text: Validation of large data sets exemplifying 
the performance of non-animal-derived antibodies in different applications and from 
various sources
IV.a  Example 1: From Collwill et al., (2011) and Mersmann et al., (2010)
The following data were generated as part of an unfunded pilot study organised by the Structural Genomics 
Consortium (SGC). In the pilot study, 20 SH2 domain proteins were selected as antigens due to their broad 
interest to the scientific community. They are also a challenging test set, owing to their high degree of 
sequence and structural similarities. Antigens were distributed to researchers in five laboratories for antibody 
generation. One group generated monoclonal antibodies by using hybridoma technology. The other groups 
generated recombinant fragment antigen-binding (Fab) or scFv reagents using phage display. Antibody 
candidates were analysed by enzyme-linked immunosorbent assay (ELISA) to determine the selectivity of 
binding for the cognate SH2 domain over other SH2 domains and scored as positive if the signal for their 
cognate targets was ten times above the off-target background. A subset of the ELISA data is shown in the 
following figure (Figure I).
Table I: Summary of various international consortia supporting large scale production and characterisation of non-animal-
derived antibodies; scFv = Single-chain fragment variable; scFv-Fc = scFv dimerised by the fragment constant (Fc) domain; 
DARPin = designed ankyrin repeat proteins; Fab = fragment-antigen binding.
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Figure I: (Reprinted with permission from Mersmann et al., 2010, New Biotechnology 27, p. 122, © 2009, Elsevier B.V.) ELISA data from 12 SH2 antigens by one of the groups generating scFv 
antibodies (gene libraries HAL4/7), shown in graphical form: Single clone antigen ELISA data of the first screening campaign on microtiter plates. 92–96 antibody clones were randomly picked (per 
antigen). Bars showing the binding to the panning antigen are in green, to negative control antigen (hen egg lysozyme) in brown.
© 2009, Elsevier B.V.
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Antibodies that passed primary validation were further analysed by surface plasmon resonance to determine 
on rate (kon or ka), off rate (koff or kd) and dissociation constant (KD) as shown in the following table (Table II). 
As a measure of their specificity to their antigen at its specified molecular weight, a subset of the data from 
analysis by immunoblot is also shown. The data is derived from three phage display libraries: a synthetic Fab 
library (Sidhu and Koide laboratories, Toronto, Canada), a human naïve scFv library (McCafferty laboratory, 
Cambridge, UK) wand another human naïve scFv library (Dübel laboratory, Braunschweig, Germany), both 
derived from human donors.
Table II:  (Reprinted with permission from Collwill et al., 2011, Nature Methods, 8, p. 553, © 2011, Springer Nature) Surface 
plasmon resonance analysis and biological validation of 73 non-animal-derived antibodies.
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IV.b  Example 2: Data sets of commercially available non-animal-derived antibodies from Abcalis, 
Adipogen and Bio-Rad (other sources are available):
Abcalis: https://abcalis.com/. This data set lists (currently) 16 non-animal-derived antibodies (scFv-Fc-
antibodies generated after selecting scFv from universal naïve gene libraries HAL4/7/8 and HAL9/10 derived 
from human B cells) that have been identified as positive by primary ELISA screen. In each case, the original 
citation is given where the antibody performance is demonstrated by a range of immuno-analysis techniques, 
often including tissue stainings, fluorescence-activated cell sorting (FACS) or even detailed functional assays, 
like antigen neutralisation. Most have been mapped to bind a specific epitope sequence and the binding 
affinity (KD) of some is given.
Adipogen: https://adipogen.com/pub/media/wysiwyg/Catalogs/PDFs/INSIGHTS_Recombinant_Antibodies_2019.
pdf. This data set lists 20 different antibody clones (RecMAbs™) produced without the use of animals, 
developed by antibody phage display technology using two different human naïve scFv antibody gene libraries 
obtained through collaboration with two research groups from different countries. The selected monoclonal 
scFv, identified as positive by primary ELISA screen, were cloned into an appropriate vector containing a Fc 
portion of interest and then produced in mammalian cells to generate an immunoglobulin G (IgG) like scFv-Fc 
fusion protein. https://adipogen.com/antibodies.html?apg_product_type=118&p=4.
Bio-Rad: https://www.bio-rad-antibodies.com/primary-antibodies-monoclonal-polyclonal.html#isotype=HuCAL%20
Fab%20bivalent|HuCAL%20Fab%20monovalent. This data set uses the Human Combinatorial Antibody Library 
(HuCAL®) which is a fully human, synthetic monoclonal antibody library in Fab format. Selected non-animal-
derived antibodies were validated by a variety of end points including ELISA, immunoblot, immunoprecipitation, 
flow cytometry and IHC. Data for the immuno- analysis techniques employed and their corresponding 
references, where possible, are given for 158 different HuCAL antibody clones. Those converted to IgG format 
are not included in this link.
IV.c  Example 3: From Frenzel et al. (2016)
To illustrate the suitability of non-animal-derived antibodies for clinical use, the table in the link below (open 
access source) lists 60 antibodies from naïve, synthetic or semi synthetic scFv or Fab libraries from various 
Figure II: (Reprinted with permission from Mersmann et al., 2010, New Biotechnology, 27, p. 125, © 2011, Elsevier) Immunoblot 
data from SH2 antigens by one of the groups generating scfv antibodies where 1 μg of each SH2 domain was run on a 
15% SDS-PAGE gel. ScFv fragments were used to stain immunoblots of their corresponding antigens. Detection: anti-myc-
tag-antibody followed by an anti-mouse AP conjugate. Staining with nitro blue tetrazolium (NBT) and 5-bromo-4-chloro-3’-
indolyphosphate (BCIP).
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sources. These antibodies are evaluated in clinical studies or already approved for therapy by the European 
Medicines Agency or the United States Food and Drug Agency.
https://doi.org/10.1080/19420862.2016.1212149 or
https://www.tandfonline.com/doi/figure/10.1080/19420862.2016.1212149?scroll=top&needAccess=true.
IV.d  Example 4: From Huang et al. (2015)
To test a high-throughput synthetic antibody generation system, human Src Homology 3 (SH3) protein domains 
were selected as antigens against which antibodies were selected using a synthetic Fab-phage library (Library 
F, University Toronto, Canada) with a highly diverse (3×1010 unique members) repertoire Positive Fab clones 
were identified as having a cognate antigen ELISA signal at least 10-fold greater than the signal against three 
negative controls. Since some clones selected in the primary screen could have the same sequence, clones 
were DNA sequenced which revealed 216 unique Fab-phage clones, each of which bound specifically to one 
of 58 SH3 protein domains. The selected Fab antibody ID, its unique peptide sequence and its association to 
the corresponding antigen is shown in the following table (Table III). As a measure of affinity, kon, koff and KD 
data is given for 6 of the antibodies.
Table III:  (Reprinted with permission from John Wiley and Sons: Huang et al., 2015, Protein Science 24, p. 1892, © 2015, The 
Protein Society) Complementarity-determining regions (CDR) sequences and binding kinetics of Fabs. Positions randomised 
within each of the CDRs are shown at the top of each column numbered according to ImMunoGeneTics (IMGT) standards. For 
each SH3 domain antigen, abbreviated protein codes corresponding to the Uniprot recommended gene codes are provided to 
unambiguously identify the parent protein, and its position relative to the total number of SH3 domains in the parent protein is 
denoted numerically (e.g., ITSN2-2/5 represents the second of five SH3 domains in the protein ITSN2). The binding parameters 
kon (on rate), koff (off rate) and KD (affinity constant) were determined from kinetic analysis of Fabs binding to immobilised 
antigens measured by surface plasmon resonance. Sequences are shown for 65 Fabs raised against 12 antigens.
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IV.e  Example 5: From Hornsby et al. (2015)
This multicentre, NIH funded project (U54 HG006436) was launched by Rutgers University, the Structural 
Genomics Consortium (SCG) and the Recombinant Antibody Network (RAN) to rapidly develop and implement 
a high-throughput pipeline designed to generate high quality renewable recombinant antibodies. It describes 
an industrialised platform to generate antigens and validated recombinant antibodies focusing on proteins 
involved in chromatin biology including 346 transcription factors (representing >18 protein domain folds) 
and 211 epigenetic antigens. The study utilised a highly stable and diverse synthetic Fab scaffold developed 
at University Toronto, Canada (libraries E and F). These cloned antibodies are available to the academic 
community for research purposes through the recombinant-antibodies.org (RAN) to allow a more system-
wide analysis of transcription factors and chromatin biology. A summary table (Table IV) for the 670 Fabs that 
passed primary and secondary validation criteria is shown below. For a more detailed account, go to https://
www.ncbi.nlm.nih.gov/pmc/articles/PMC4597156/, supplementary materials, table S1 4.
Antibodies passed primary validation if they were able to bind their cognate immobilised antigen in the 
presence of 20nM of the same competing soluble antigen (competitive ELISA) and achieve a ratio (OD650/
min of competitive binding divided by the OD650/min of direct binding) of < 0.5. Antibodies passed secondary 
validation if they were able to bind to their parent antigen in a cellular lysate (spiked IP) since lysate may 
contribute to high-level non-specific binding and reduce specificity. Non-specific binding was estimated by the 
reduction in the direct binding (ELISA EC50) of antibody to antigen in the presence of non-cognate protein 
from baculovirus extract.
IV.f  Example 6: From Schofield et al. (2007)
This study describes the generation of non-animal-derived antibodies on a genome-wide scale in order to gain 
information about protein interaction, expression, modification and sites of action by using renewable, defined 
and homogenous reagents. As phage display technology can be adapted to a 96-well format, hundreds of 
antigens can be handled in parallel and the entire selection process can take as little as two weeks. This 
approach demonstrated that generating synthetic antibodies on a proteome-wide scale is an achievable goal.
Table IV: (Reprinted under CC BY 4.0 from Hornsby et al., 2015, Molecular & Cellular Proteomics, 14, p. 2841, © 2015, American 
Society for Biochemistry and Molecular Biology) Ability of antigens to produce primary and secondary validated Fabs as a 
function of antigen domain. Of the 537 TF antigens, representing at least 18 discrete domain types, 435 (81%) successfully 
generated sequence unique Fabs that passed competition ELISA. For 193 antigens with Fabs entering secondary validation, 108 
(56%) passed the Spiked-IP validation test. The best performing domains are the Forkhead, SCAN, JMJ, and BTB domains with 
success rates of 100%, 88%, 100%, and 86% respectively.
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The scFv library was generated using B-lymphocytes from 42 human peripheral blood donations and 1 tonsil 
and cloned into PSANG4 vector. Antibodies were selected to 404 antigen targets (representing 280 genes), the 
majority (214/280) being cell surface receptors. Large-scale generation of 4,400 antibodies were characterised 
to 292 antigens by ELISA. Detection sensitivity was measured for 100 antibodies to 10 antigens using a bead 
based flow cytometry assay. Representative histograms for antigen Jagged-1 (a ligand for Notch receptors 
expressed on embryonic stem cells) are given below to show that performance in the bead assay correlates 
with ability to detect endogenous levels of antigen (Figure III). This shows that signal intensity varies with 
different antibodies and this, in turn, corresponds to the performance ranking found in the bead based assay.
The bead assay was applied to 90 other antibodies representing nine different target genes. In this experiment 
beads were coated with antigen at a range of densities (18,000, 57,000, 459,000 antigens/bead). To help 
summarise and present the results for all 90 antibodies, the median fluorescent intensity for the bead coated 
with 459,000 target molecules was calculated (Table V).
Figure III: (Reprinted under CC BY 4.0 from Schofield et al., 2007, Genome Biology, 8, p. R254.8, © 2007, Springer Nature) Flow 
cytometry calibration beads with varying number of anti-human Fc antibodies were coated with Jagged-1-Fc fusion to yield 
antigen display levels of 29,000, 83,000, 204,000 and 619,000 Jagged-1 molecules/bead. These were labelled with a panel 
of different recombinant antibodies raised against Jagged-1 and binding was detected with labelled anti-FLAG antibodies. The 
resulting histograms are shown, giving different levels of sensitivity. In Jag1_D5 for example, five peaks are visible corresponding 
to uncoated beads and each of the four antigen coated beads. In the case of Jag1_C5, where there is lower sensitivity, only the 
two beads with highest density are resolved while the others merge with that of the uncoated bead. Where all four beads are 
clearly resolved, the theoretical limit of detection of receptors per bead (Rec. #) is calculated. The primary peak and CD4_B5 
respectively represent fluorescence in the absence of antibody and non-specific antibody binding negative controls.
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V  Non-animal-derived antibody resources
V.a  Catalogue antibodies
Some non-animal-derived antibody catalogue companies (defined here as non-animal-derived affinity ligand) 
can be exemplified:
• Abcalis (exclusively offers non-animal-derived antibodies, all from human phage display libraries)
• Abcam (14 non-animal-derived antibodies, all affibodies)
• Adipogen (21 non-animal-derived antibodies, all from human phage display libraries)
• Affibody (~ 40 non-animal-derived antibodies, all affibodies)
• Amsbio (~ 80 non-animal-derived antibodies, all aptamers)
• Avacta (23 non-animal-derived antibodies, all affimers)
• Bio-Rad Antibodies (~ 300 non-animal-derived antibodies in catalogue, all from a human synthetic library)
• Recombinant Antibody Network (RAN - 850 scFv-Fc antibodies) https://proteincapture.org/about/ran/
• Source Bioscience, ATLAS (2,400 scFv antibodies) https://www.sourcebioscience.com/media/1261/
proteomic-resources-atlas_db_new.xls
Table V: (Reprinted under CC BY 4.0 from Schofield et al., 2007, Genome Biology, 8, additional data file 2, © 2007, Springer 
Nature) Flow cytometry calibration beads were coated with various antigen densities/bead, analysed by flow cytometry and the 
relative median fluorescent intensity of the bead with 459,000 copies/bead was calculated. Shown are the actual values and 
the clone identifications associated with them. At the flow cytometry settings used, the uncoated bead gave a score of 0.1-0.2.
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V.b  Custom generation of non-animal-derived antibodies
 
• University of Geneva (non-commercial, limited to research purposes): https://www.unige.ch/
medecine/antibodies/
• Centre for the Commercialisation of Antibodies and Biologics (CCAB): https://ccabcanada.com/
• Bio-Rad: https://www.bio-rad-antibodies.com/custom-monoclonal-antibody-generation.htm
• Yumab: https://yumab.com/
• University of Zurich (DARPin platform, limited to academic users): http://www.bioc.uzh.ch/research/
core-facilities/high-throughput-binder-selection/
V.c  Phage display antibody library construction
The following is a non-exhaustive list of organisations offering phage display antibody library construction from 
non-animal sources, although not necessarily exclusively restricted to non-animal-derived sources. Libraries 
may be limited to research purposes or available for out-licensing to the biotechnology and pharmaceutical 
community,
• Source Bioscience, Human Domain Antibody Library (DAb): https://www.sourcebioscience.com/
products/life-sciences-research/clones/artificial-antibody-libraries/human-domain-antibody-
library-dab/
• Iontas: https://www.iontas.co.uk/IONTAS-services/phage-display-library-construction/
• Creative Biolabs: https://www.creative-biolabs.com/phage-display-library-construction.html?gc
lid=cjwkcajwstfkbrboeiwadtmnecopc3uweashyemjm_4jmdo4zxpskz0utwostqp9ol7iwwrcnfu-
yhocnyuqavd_bwe
• Biologics International corp: https://www.biologicscorp.com/phage-display-antibody-library-
construction.html#.XJZr4iL7TIU
• Oak Biosciences https://www.oakbiosciences.com/services/antibodyengineering/antibody-library-
construction/
• Yumab: https://www.yumab.com/contract-research/libraries/
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